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ABSTRACT 
 
 Aims and Objectives:  
 
 The fat stores in our body secrete many hormones and cytokines that not only 
regulate the energy balance but also regulate the inflammatory and immune responses. 
Among them leptin has been investigated widely as a proinflammatory cytokine in the 
pathogenesis of several inflammatory autoimmune diseases. Therefore this study was 
designed to measure the serum leptin levels in Rheumatoid Arthritis(RA) patients and 
to compare it with healthy controls and also to correlate  serum leptin levels in 
Rheumatoid arthritis patients with their disease activity.  
 
Methodology:   
 Sixty adult RA patients and 30 sex and age matched healthy controls were 
selected for this case control study. Serum leptin, C-reactive protein, lipid profile, uric 
acid, urea, creatinine and ESR were estimated in the study subjects. The disease 
activity in RA patients was assessed using the DAS 28(3) scoring system. Body mass 
index (BMI) was calculated for both RA patients and controls using Quetelet index. 
Estimation of serum leptin levels in RA patients and controls was done using DRG 
Leptin ELISA Kit. 
 
Results:   
 RA patients showed statistically significant higher mean serum leptin level than 
healthy controls (48.78+ 32.00ng/mL versus 11.94+6.11ng/mL respectively, 
p=<0.001). However no significant correlation was observed in RA patients between 
serum leptin level and disease activity (p= 0.240). But the serum leptin level showed a 
statistically significant positive correlation with body mass index (p= 0.001) and C-
reactive protein (p= 0.001).  
 
Conclusion:   
 As the serum leptin levels were significantly higher in the RA patients  than in 
the controls it is understood that leptin plays a pivotal role in the pathogenesis of  RA 
as a proinflammatory cytokine. However no correlation was observed between serum 
leptin levels and disease activity of the RA patients. But the serum leptin levels 
correlated well with body mass index indicating that the body fat stores can also 
decide upon the incidence of RA. The study also demonstrated a good correlation 
between serum leptin levels and C- reactive protein proving leptin as a inflammatory 
marker.  
 
Keywords: Rheumatoid Arthritis, Serum Leptin , DAS28(3), BMI, C-reactive 
protein. 
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INTRODUCTION 
 
 Rheumatoid Arthritis is an autoimmune disease affecting 0.5-1% of 
general population.1 Women are more often affected than men in the ratio of 
3:1.2 Recent studies have shown that the hormones secreted by the adipocytes 
like resistin, leptin and adiponectin act as new mediators of the inflammatory 
process.3 Among all, leptin has been found to play a major role in the 
pathogenesis of Rheumatoid Arthritis. 
 
 Leptin is a 16KDa peptide synthesized by white adipose tissue(WAT).  
Leptin and its receptors Ob-R show structural and functional similarities with 
cytokines of  IL-6 family and their  receptors.4 Though Leptin’s major role is to 
regulate food intake and energy expenditure, few of the other important 
peripheral functions include  regulation of endocrine function, reproduction and 
immunity. Proinflammatory mediators like IL-1, IL-6 etc also mediate leptin 
expression.. In both acute and chronic inflammation circulating leptin levels are 
found to be increased.  Leptin modulates TH1/TH2 balance,  regulating 
cytokines expression pattern. In synergy with other cytokines,  leptin has been 
found to induce NOS type II activation in chondrocytes.5 
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 Many clinical in vitro, in vivo animal and human studies suggests the 
involvement of leptin in the pathogenesis of Rheumatid Arthritis. Hence in this 
study we assess the role of leptin in Rheumatoid Arthritis and thereby aid in 
future prospective studies in the control of undesired leptin action  in 
autoimmune inflammatory diseases.  
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REVIEW OF LITERATURE 
 
RHEUMATOID ARTHRITIS  
 Rheumatoid Arthritis (RA) is a chronic systemic autoimmune 
inflammatory disorder characterised by symmetrical synovitis, polyarthritis, 
progressive joint damage, pain, fatigue and disability. It is due to complex 
interaction between genes and environment which causes break down of 
immune tolerance leading to symmetrical synovial inflammation. 
 
 EPIDEMIOLOGY: 
A) PREVELANCE INCIDENCE OF RA 
 It is the most common inflammatory disorder affecting 0.5 – 1% of the 
general population in the world.1 The prevalence of the disease is constant 
worldwide but few exceptions can be seen as in China where the incidence is as 
low as 0.3% and it is 5% in PIMA Indians of North America.6 The onset of the 
disease is commonly seen in the fourth or fifth decade of  life.7 Most of the 
studies  show  a female : male ratio of  2:1 or 3:1.2 Age specific prevalence rate 
have been found to increase with age and the sex difference has been found to 
decrease in older age group. 
 
 In the Indian adult population also it is the most common inflammatory 
disease with an incidence of approximately 0.75%.8 
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FACTORS ASSOCIATED WITH INCREASED RISK OF RA: 
a) Host Factors: 
i) Age: 
 The incidence of RA increases with advancing age. Old age is 
characterised by immune senescence. Due to immune senescence there is 
massive expansion of lymphocyte clone, erosion of leucocyte telomerase & 
corresponding contraction of naive T and B cell repertoires. Derangements are 
noted in pathways integral to antigen responsiveness and immune regulation. 
This leads to increased susceptibility to foreign pathogens, augmented 
reactivity to self-antigens and a repertoire of lymphocytes defective in tumour 
surveillance is generated. Therefore immune senescence in old age can be 
considered as a risk factor in the development of autoimmune diseases.9 
 
ii) REPRODUCTIVE & ENDOCRINE FACTORS: 
 As more number of cases are seen among the female population and that 
too before menopause, a signifigant role by reproductive and hormonal factors 
have been suggested. Increased risk is seen among nulliparous women and 
those who have recently given birth. Higher incidence of rheumatoid arthritis  
is seen among women with history of preeclampsia, hyperemesis or gestational 
hypertension. 
 
 Breast feeding has been found to have reduced risk of developing 
rheumatoid arthritis.10 Onset of menopause before the age of 45years has been 
found to be associated with increased risk of developing rheumatoid arthritis.11 
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 Studies on the effect of oral contraceptive pills in the development of 
rheumatoid arthritis have been conflicting and some reports suggesting an 
inverse relationship with higher estrogen content.12  
 
iii) BIRTH WEIGHT: 
 Birth weight more than 4Kg has been associated with increased risk of 
developing rheumatoid arthritis.13 The exact pathophysiology is not known, but 
it is hypothesized that the pathology may be due to hypothalamo – pituitary 
axis dysfunction which is associated with both high birth weight and 
rheumatoid arthritis. 
 
b) ENVIRONMENTAL FACTORS: 
i) LIFESTYLE: 
1) Cigarette Smoking: 
 Cigarette smoking, is the strongest known modifiable environmental 
risk factor14and has been found to be strongly associated with ACPA positive 
(Anti Citrullinated Protein Antibodies) and RF positive rheumatoid arthritis.15 
The risk increases with intensity (number of cigarettes per day) & duration of 
cigarette usage.  Smokers who carry risk alleles in the Human Leukocyte 
Antigen Shared Epitope (HLA – SE) develop rheumatoid arthritis and this 
suggests the role of gene– environment interaction in smokers. Smoking 
increases the proportion of citrulline +ve cells in the lungs, which provides 
systemic antigen exposure that can contribute to Anti-CP antibody production 
and risk of developing rheumatoid arthritis later.16Other genes that have been 
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implicated to increase risk of developing RA among smokers include genes 
coding for enzymes that detoxify carcinogens  namely   
 
 Glutathione S transferase genes 
 Hemeoxygenase gene 1 (HMOX1) 
 N – Acetyl transferase 2 (NAT2) 
 
2) Alcohol:  
 Studies have shown that alcohol consumption reduces the risk of 
developing RA, especially ACPA+ve RA.17 
 
Obesity:  
 Obese individuals with body mass index of more than 30 have been 
found to be associated with increased incidence of RA.18  
 
NUTRITION: 
 Influence of diet on the risk of developing RA is variable. Some studies 
suggested a high protein diet and red meat intake is associated with increased 
risk of inflammatory arthropathy.19Consumption of olive oil and fish oil has 
been reported to protect against the risk of developing rheumatoid arthritis.  
 Vitamin D being a modulator of immune response, its deficiency is 
found to be associated with increased risk of developing RA.  
 Some studies have suggested a link between RA & deficiency of copper 
and selenium. Vitamin C rich diet reduces the risk of inflammatory 
polyarthritis.   
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ii) MEDICATIONS: 
 Use of statins by individuals with hyperlipidemia reduces the risk of 
developing RA as statins have modest anti-inflammatory effects.20 
 
INFECTIOUS AGENTS: 
 There is no epidemiological evidence for an infectious cause for 
rheumatoid arthritis. In some patients after diagnosing rheumatoid arthritis 
increased titres of antibodies to Ebstein Barr virus have  been found. 21In 
females with rheumatoid arthritis antibodies to human parvo virus was found to 
be increased.22  
 
iii) SOCIOECONOMIC STATUS AND OCCUPATION:  
 In recent studies an inverse relationship has been found between 
socioeconomic status and risk of rheumatoid arthritis. 
 
 Exposure to silica dust and mineral oil is associated with increased risk 
of rheumatoid arthritis.23 
 
iv) URBAN AND INDUSTRIAL ENVIRONMENT: 
 A general association has been found between rheumatoid arthritis and 
urban industrialised environment. Traffic pollution exposure is associated with 
increased risk for rheumatoid arthritis.24 
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ETIOLOGY:  
 The etiology of rheumatoid arthritis remains unknown, but a variety of 
studies have suggested an interaction between environmental and genetic 
factors responsible for development of rheumatoid arthritis. 
 
 Family studies have indicated a genetic predisposition. Severe 
rheumatoid arthritis has been seen in the 1st degree relatives of individuals 
having disease associated with presence of autoantibodies, RF; and it is 
approximately 4 times the expected rate.  It has also been observed that 
approximately 10% of rheumatoid arthritis patients will have an affected 1st 
degree relative.  Moreover monozygotic twins are 4 times concordant for 
rheumatoid arthritis than the dizygotic twins,who have a similar risk as non 
twin sibling. Only 15 -20% of monozygotic twins are concordant for 
rheumatoid arthritis implying that factors other than genetics play an important 
role in the etiopathogenesis of RA.  
 
 In immunogenetics, the most influential genetic risk factor has been the 
class II MHC haplotype of an individual. Protein Tyrosine Phosphatase 22 
(PTPN22) and Peptidyl Arginine Deiminase 4 (PADI4) increases the risk of 
rheumatoid arthritis in some ethnic and racial groups. So far 35 genes involved 
with immune function have been implicated. Combination of HLA - DR, 
PTPN22 and TRAF1-C5 interact with one another and cause a 45 fold increase 
in the risk.25 This combination is seen in less than 1% of the individuals with 
rheumatoid arthritis. 
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i) ROLE OF HLA-DR: 
 The increased susceptibility and severity of rheumatoid arthritis is 
associated with the structure of class II MHC molecules present on the antigen 
presenting cells and it accounts for about 40% of genetic influence. 70% of 
rheumatoid arthritis patients have HLA-DR4 compared to 30% of the controls, 
and so the relative risk of developing rheumatoid arthritis in HLA-DR4 
individuals is approximately 4 to 5. 
 
 The third hypervariable region of DRβ chains from aminoacids 70 to 74 
is associated with increased susceptibility to rheumatoid arthritis. The sequence 
of the epitope found in DR4, DR14 and some other DR1β chain is glutamine – 
leucine – arginine – alanine –alanine (QKRAA). The “susceptible epitope” 
(SE) on DR4β chain that has great association with rheumatoid arthritis are 
DRB*0401, DRB*0404, DRB*0101and DRB*1402.26 Some HLA genes like 
DRB*1301 have DERAA sequence that has decreased susceptibility to 
rheumatoid arthritis.27  
 
 Patients who do not fit into this paradigm exhibit microchimerism.28 The 
susceptible epitope (QKRAA) expressed by the maternal cells can persist 
throughout adulthood and these non inherited maternal antigens (NIMA) 
confers increased risk. 
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 Molecular mimicry is also observed in some situations where the 
susceptible epitope  (QKRAA) serve as an autoantigen. Certain proteins such 
as gp110 from Ebstein Barr virus also share this sequence. 
 
ii) ADDITIONAL POLYMORPHISM: CYTOKINES, 
CITRULINATING ENZYMES, PTPN22 AND OTHERS: 
 Some non MHC genes have also been evaluated for genetic influence on 
rheumatoid arthritis. Single nucleotide polymorphism(SNP) has been studied 
extensively in rheumatoid arthritis. Table below shows some of the SNPs and 
microsatellites associated with rheumatoid arthritis.  
 
TABLE1: Genetic associations in RA. 
Gene 
Odd’s Ratio For Risk 
Alleles 
Comment 
HLA-DR 
PTPN22 
PADI4 
TRAFI-C5 
STAT4 
TNFAIP3 
IL2/21 
4-5 fold 
=2fold 
=2fold 
>1.2 fold;<2fold 
>1.2 fold;<2fold 
>1.2 fold;<2fold 
>1.2 fold;<2fold 
 
Not in Asian populations 
Primarily in Asian populations 
 
Courtesy  KELLY’S Textbook of Rheumatology, 9th edition, pg.1062.                
 
 Cytokines also play an important role in the pathogenesis of rheumatoid 
arthritis, among which Tissue necrosis factor(TNF) plays a major role. It’s 
genes are located on chromosome 6.29  
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 The noncytokine and non MHC genetic linkages involved in rheumatoid 
arthritis are : 
 Peptidyl arginase deiminase (PADI) 
 Protein Tyrosine phosphatase 22 (PTPN22) 
 
 Four  isoforms of PADI genes are identified, PADI1 to PADI4.  PADI4 
gene SNPs are noted in Japanese population and they have a twofold increased 
risk for rheumatoid arthritis.30   
 
 PTPN22 gene SNPs have also been found to have a twofold increased 
risk in the development of rheumatoid arthritis. PTPN22, a phosphatase 
regulates the phosphorylation of various kinases required for T cell 
activation.31 
 
 Genes associated with rheumatoid arthritis, regulating adaptive immune 
responses in T cells include: 
 Protein Tyrosine Phosphatase – 22 (PTPN22)  
 Cytotoxic T – lymphocyte associated protein (CTLA) 
 
 Other genes implicated in rheumatoid arthritis and associated with  
B – cell and /or antigen presenting cells are 
 B and T – lymphocyte attenuator (BTLA) 
 Fc  receptors  
 CD40  
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 Signal transduction pathways regulating the immune function like 
TRAFI – 5 and STAT 4 have also shown exhibit polymorphism. 32 
 
iii) INTERACTION BETWEEN GENES AND ENVIRONMENT: 
 There are many environmental factors contributing to rheumatoid 
arthritis but among them smoking has been considered as a major 
environmental risk factor for seropositive rheumatoid arthritis. In smokers there 
is activation of innate immunity and PADI in the airway and this has led to the 
citrullination of proteins which are found in their bronchoalveolar lavage. This 
then stimulate the generation of ACPAs in susceptible individuals leading to 
development of rheumatoid arthritis. Smokers with two copies of “SE” have a 
40 fold increased risk of developing rheumatoid arthritis due to the increased 
ability of the HLA-DR molecules containing the “SE” to bind some 
citrullinated proteins. Also studies show that the risk declines only slowly after 
cessation of smoking  and may take more than a decade to reach that of non 
smokers. 
 
 Alcohol consumption has been found to decrease the risk, while 
exposure to inhaled irritants like silica dust increases the risk of developing 
rheumatoid arthritis. Oral contraceptive pills has been observed for its 
protection from rheumatoid arthritis, due to the changes in the hormonal 
balance. 
 
 Therefore there is complexity in understanding the environment and 
human behaviour on disease susceptibility. 
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iv) GENDER: 
 Rheumatoid arthritis is one among the many autoimmune diseases that 
predominate in women. The ratio between male and female patients is 1:2 to 
1:3. This has been found to be due to estrogens and some studies have 
supported the concept that the immune function is modulated by estrogens. 
Fibroblasts like synoviocytes(FLS) express estrogen receptors increasing the 
production of metalloproteinases. Moreover estrogen causes enhanced 
production of tissue necrosis factor (TNF) by macrophage cell lines. 
 
 The last trimester of pregnancy in rheumatoid arthritis patients is often 
associated with remission of disease. This has been thought to be due to 
alterations in cell mediated immunity, expression of suppressive cytokines like 
IL-10 or production of α-fetoprotein.33 
 
V)     EPIGENETICS: 
 Epigenetics describes the phenotypic or genome expression properties 
caused by mechanism other than changes in the underlying DNA. In 
rheumatoid arthritis most information on epigenetics comes from studies on 
rheumatoid arthritis synovium or cultured synoviocytes. In rheumatoid arthritis 
synovium low levels of DNA methylase( Dnmtl) is expressed.34  Ingestion of 
methyl donors like folate or exposure to methyl donors in utero can alter 
methylation of DNA and adaptive immune function, thereby affects the 
susceptibility to autoimmune disease.  
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PATHOGENESIS: 
 
Figure1: Disease mechanism in RA.  
Courtesy KELLEY’S Textbook of Rheumatology. 9th edition, pg.1060. 
 
 A single specific “ rheumatoid arthritis pathogen” is not established but 
viruses, retroviruses, bacteria and mycoplasma have been associated with 
rheumatoid arthritis. Due to repeated inflammatory stress through specialised 
receptors that respond to common molecules produced by the pathogens, in a 
genetically susceptible individual might lead to breakdown of tolerance and 
subsequent autoimmunity. 
I) INFECTIOUS AGENTS: DIRECT INFECTION AND INNATE 
IMMUNITY RESPONSES: 
 Infectious agents can initiate immune response by various mechanisms. 
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TABLE2: Possible infectious causes of RA. 
        Infectious Agents                    Potential Pathogenic Mechanisms 
Mycoplasma 
Parvovirus B19 
Retroviruses 
Enteric bacteria 
 
Mycobacterium 
 
 
Epstein-Barr virus 
Bacterial cell walls 
Direct Synovial Infection; Superantigens. 
Direct Synovial Infection. 
Direct Synovial Infection. 
Molecular mimicry (QKRAA,e.g., In Bacterial Heat 
Shock proteins) 
Molecular mimicry (Proteoglycans,QKRAA), 
Immunostimulatory DNA (Toll-like receptor 9 
activation.) 
Molecular mimicry (QKRAA in gp110) 
Toll-like receptor 2 activation. 
Courtesy KELLEY’S Textbook of Rheumatology, 9th edition, pg 1065.                
 
 Toll like receptors, expressed by the sentinel cells of the host provide 
first line of defence. These receptors could recognize the preserved structures 
of the bacteria and other infectious agents leading to release of inflammatory 
mediators, activating the antigen presenting cells and enhancing adaptive 
immune responses.  
 
 In human beings at least 11 Toll-like receptors are identified. TLR2  
binds peptidoglycans, TLR3 binds double stranded RNA (dsRNA), TLR4 
binds lipopolysaccharide and TLR9 binds bacterial DNA containing CpG 
motifs. Rheumatoid synovial tissue expresses many of these pattern recognition 
receptors. “Exogenous” TLR ligands like bacterial peptidaglycan and DNA, as 
well as “endogenous” ligands like heatshock protein, hyaluronan and 
fibrinogen are seen in arthritic joints.35  
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 Inflammasome is a novel structure that regulates the innate immunity 
through the second mechanism. This complex consists of several proteins that 
recognises the “danger signals” and pathogens like muramyl peptides and uric 
acid. Cryopyrin (NALP3) is one such complex, that is linked to caspase 1(IL-
1convertase). So when the inflammasome gets engaged caspase 1 is activated 
and IL-1 is produced. 
 
i) BACTERIA, MYCOBACTERIA, MYCOPLASMA AND THEIR 
COMPONENTS: 
 Most rheumatoid arthritis synovium contains bacterial DNA sequence 
such as that of Acinetobacter and Bacillus spp. The “synovium” functions as an 
adjunct to the reticuloendothelial system in arthritis and allows the local 
macrophages in accumulating the circulating bacterial products. TLRs are 
expressed by the antigen presenting cells containing these products and these 
produce proinflammatory cytokines like TNF. Superantigens of mycoplasma, 
such that of Mycoplasma arthridis can directly cause induction of T-cell 
independent cytokine production by macrophages, thus exacerbating or 
triggering arthritis. Higher prevalence of antimycoplasma pneumonia IgG 
antibodies is seen in rheumatoid arthritis patients than in controls.36 
 
ii) EBSTEIN- BARR VIRUS, DNA J PROTEINS AND MOLECULAR 
MIMICRY: 
 Ebstein Barr Virus is an activator of polyclonal B lymphocyte and 
increases the production of Rheumatoid Factor. Moreover there is defective 
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suppression of EBV induced proliferation of  B cells by rheumatoid 
macrophages and T cells. This has been attributed to the homology between the 
“susceptibility cassette” in HLA-DR proteins and the EBV glycoprotein gp110. 
Like DRB*401, QKRAA motif is seen in gp110 protein and serological 
evidence of antibodies against this epitope is observed in patients with previous 
history of EBV infection. 
 
 Therefore the T cell recognition of EBV epitope in some patients with 
“SE” can cause an immune response directed against the synovial cells through  
“molecular mimicry”. 
 
 Like gp110 there are many other xenoproteins exhibiting the same 
QKRAA motif and among them Escherichia coli heat shock protein dnaJ is 
important. Rheumatoid arthritis T cells, especially the synovial fluid T cells 
show increased proliferative response to gp110 thus supporting the molecular 
mimicry link existing between a variety of QKRAA containing proteins and 
rheumatoid arthritis.37 
 
iii) PARVOVIRUS: 
 Parvovirus B19 DNA has been detected in 75% of rheumatoid arthritis 
synovium. B19 protein VP-1 has been detected in patients with rheumatoid 
arthritis. The mechanism involved in B19 induced synovitis has been related to 
alteration in FLS function. 
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OTHER VIRUSES: 
 Studies of synovial tissues have demonstrated DNAs of many other 
viruses like rubella virus, cytomegalovirus and herpes simplex virus. It has 
been observed that one or more of these infections could trigger the disease in 
the genetically susceptible host. 
 
II) AUTOIMMUNITY:  
 There is evidence of autoimmunity present in patients with rheumatoid 
arthritis many years before the onset of clinical symptoms. Autoantibodies  
commonly associated with rheumatoid arthritis include RF and anticitrullinated 
protein antibodies(ACPAs).  
 
 Autoantibodies  in rheumatoid arthritis recognizes joint antigens like 
Type II collagen or systemic antigens like glucose phosphate isomerase leading 
to synovial inflammation through several mechanisms. 
 
TABLE 3 Autoantigens in RA 
Cartilage Antigens Other Antigens 
Type II Collagen Immunoglobulin G 
gp 39 Citrullinated proteins 
Proteoglycans Glucose-6-phosphoisomerase 
Aggrecan HLA-DR (QKRAA) 
Cartilage link protein Heat shock proteins 
 
Courtesy KELLEY’S Textbook of Rheumatology, 9th edition, pg 1069.               
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i) RHEUMATOID FACTOR (RF): 
 The first direct evidence of autoimmunity in rheumatoid arthritis was 
established when RF, an autoantibody that can bind Fc portion of IgG was 
identified and studied. The RF and other autoantibodies are identified in 
patients with rheumatoid arthritis many years before the onset of disease.38 
Some patients are initially “seronegative” and they become “seropositive” 
within the first year of disease activity. 
 
 Patients with RF positivity in blood exhibit more severe form of disease 
including severe cardiovascular complications.39It has been demonstrated that 
RF can fix and activate complement by classic pathway and also cause local 
complement production and consumption in rheumatoid joint. Rheumatoid 
synovial tissue produces large quantities of IgG RF forming complexes through 
self association. Rheumatoid arthritis synovial tissue and surface layers of 
cartilage express RF containing the immune complexes.  
 
 Seventy five percent of rheumatoid arthritis patients are seropositive by 
usual standard tests but it can be as high as 90% when IgM RF is assayed using 
enzyme linked immunoassay. First degree relatives of seropositive patients are 
frequently found to be RF+ve suggesting a genetic predisposition. IgG and IgM 
RFs are the most abundant in rheumatoid arthritis patients but in patients with 
extraarticular manifestations IgE RF has also been demonstrated.  
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ii) Anticitrullinated Protein Antibodies (ACPAs): 
 Immunoglobulins binding to citrullinated proteins are produced by 
rheumatoid arthritis patients. It is one of the most striking features recently 
observed and it has significant prognostic implication. Antibodies directed 
against keratin were detected in serum of rheumatoid arthritis patients and the 
primary target antigen was Filaggrin, a filament aggregating protein. These 
antibodies bind to epitopes on filaggrin containing citrulline , which is derived 
by post translation modification of arginine by PADI. Four isoforms of PADI 
are observed in humans and among them PADI2 and PADI4 are abundant in 
synovium.40 It has been studied that certain SNPs in Asian population are 
associated with rheumatoid arthritis. 
 
 CPs of the smokers’ lungs provide a systemic antigen exposure that can 
lead to production of anti CP antibodies predisposing to rheumatoid arthritis. 
Rheumatoid synovium especially tissues with lymphoid aggregates produce 
ACPAs. 
 
 Serum of 80-90% of the patients demonstrate ACPAs. The specificity of 
ACPA is near 90% and it is more specific than RF. Like RF, ACPAs are 
detected in patients with rheumatoid arthritis long before the onset of clinical 
arthritis. A genetic predisposition has been confirmed in Native American 
population, where 20% of unaffected 1st degree relatives have ACPAs in their 
serum and it is detected in more than 10% of distant relatives. 
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 Presence of ACPAs predict an aggressive disease marked by destruction 
of bone and cartilage. Anti CP positivity is observed as an independent risk 
factor for coronary artery disease.  
 
 ACPAs activate both classical and alternative complement pathways.41 
In addition Ig E ACPAs in patients with rheumatoid arthritis sensitizes 
degranulation of basophils and mast cells. This enhances the vascular 
permeability and infiltration of the synovium by inflammatory cells. 
 
 Type II collagen which is citrullinated is found to be more immunogenic 
than the native protein and this is attributed to increased affinity in the binding 
groove of HLA-DR proteins that contain the “SE”. 
 
iii) Autoimmunity to cartilage specific antigens:    
 As synovial tissue inflammation is a hallmark of rheumatoid arthritis 
some joint specific antigens play a pathogenic  role. Though there are a number 
of potential antigens there is no single antigen as “rheumatoid” antigen. 
 
a) Type II Collagen:  
 For initiation of collagen induced arthritis T cells are required and a 
major arthrogenic and  immunogenic  epitope is found to reside in a” restricted 
area” of the type II collagen chains. Type II collagen antibodies amplify the 
inflammatory process. Antibodies to denatured bovine type II collagen are 
demonstrated in sera of rheumatoid arthritis patients which is significantly 
higher than that of control sera.42 When the purified anticollagen antibodies 
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from the sera of the patients bind to the cartilage, they activate the 
complements and generate C5a. 
 
b) Glycoprotein39( gp 39): 
 Another cartilage component that has been implicated as a potential 
autoantigen in rheumatoid arthritis is cartilage glycoprotein 39 (gp39). This 
gp39 peptides bind to HLA-DR*0401 of rheumatoid arthritis patients and 
stimulate the proliferation of T cells. Only in a small percentage of patients 
antibodies to gp39 are detected but it happens to be specific for rheumatoid 
arthritis. 
 
c) Other cartilage specific antigens:     
 Proteoglycans, aggrecan and cartilage-link protein are few other 
examples of potential cartilage autoantigens. 
 
iv) Autoimmunity to non articular antigens: 
 Antigens beyond the joint also can cause autoimmune responses in RA. 
 
a) Glucose -6-Phosphoisomerase: 
 Glucose- 6- Phosphate isomerase(GPI) adheres to the cartilage surface 
and allows local antibody binding and fixation of the complement. Mast cells, 
the alternate complement pathway and the Fc receptors are required for 
initiation of synovial inflammation in this GPI induced arthritis, moreover IL-1 
is more important in this model.43 
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Heterogenous Nuclear Ribonucleoprotein A2: 
 About one third of rheumatoid arthritis patients exhibit antibodies 
directed against heterogenous nuclear ribonuclear protein A2(hnRNP-A2),  
otherwise called RA33. Less destructive disease has been observed in this 
RA33 positive patients. Though it is not sensitive or specific for rheumatoid 
arthritis, this along with RF and ACPAs can be used to predict the risk of 
erosive disease in patients with early synovitis.44 
 
Heavy chain binding protein: 
 Autoantibodies binding to stress protein immunoglobin heavy chain 
binding protein (BiP) have been identified. Anti BiP antibodies is present in 
60% of patients and the specificity is more than 90%. 
b) Heat shock proteins: 
 Heat shock proteins are produced by cells of all species in response to 
stress. Synovitis and joint destruction are caused by autoantibodies of heat 
shock proteins. 
ROLE OF T-CELL CYTOKINES:  
Figure 2 Cytokine network in RA 
 
Courtesy KELLEY’S Textbook of Rheumatology, 9th edition, pg 1093. 
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 Several subsets of T cells are involved in the etiology of rheumatoid 
arthritis. In rheumatoid arthritis factors produced by macrophages and 
fibroblast dominate and that of T cells are surprisingly low. T cell cytokines 
like IFN-γ and  IL-17 are produced by Th1 or Th17 cells. Regulatory T cell 
function is found to be low in rheumatoid arthritis synovium.  
 
i) T Helper Type I Cell Cytokines: 
 Th1 phenotype produces cytokines like IL-2 and IFN-γ and expresses 
chemokine receptors CXCR3 and CCR5. IFN-γ is a potent inducer of HLA-DR 
antigens. IFN-γ causes alteration in the balance of extracellular matrix 
synthesis and degradation by decreasing synthesis of collagen and inhibiting 
the production of matrix metalloproteinase by cytokine stimulated FLS.45  
  
ii) T Helper Type 2 Cell Cytokines: 
 IL-4, LT-α, IL-12, IL-13 and IFN-γ are the cytokines produced by Th 2 
cells and these are found in the rheumatoid synovium. IL-12 is a cytokine that 
causes T cell maturation towards the Th1 phenotype.46 
 
iii) T Helper Type 17 cytokines:  
 Th 17 cells produce the proinflammatory cytokine IL-17 which exists in 
six forms (IL-17A through IL-17F). IL-17A and IL-17F mimic IL-1 and TNF 
in many of the activities related to FLS which includes collagenase induction 
and cytokine production. IL-17A is detected in modest amounts in synovial 
effusions. 47 
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iv) Regulatory T cells (Tregs): 
 The CD4+, CD25+ and CD127+ cells are deficient in rheumatoid 
arthritis  patients. Autoimmunity is attributed to the deficiency of this subset, 
which produces TGF-β and IL-10 and regulates the T cells through cell contact.  
 
T Helper Cell Imbalance In Rheumatoid Arthritis: 
 In rheumatoid arthritis the Th1 phenotype and Th17 are demonstrated in 
relative abundance to the Th2 phenotype. The rheumatoid synovium exhibit 
Th1- like delayed type hypersensitivity reaction and /or a Th 17 autoimmune 
environment.  
 
ROLE OF MACROPHAGES AND FIBROBLAST CYTOKINES: 
 Cytokines of macrophage and fibroblast are found abundantly in 
rheumatoid synovium. Proinflammatory cytokines include IL-1, TNF, IL-6, IL-
15, IL-18, GM-CSF and IL-33. Chemokines produced by the macrophage and 
fibroblast drive inflammatory cells into the joint.  
 
 Although anti-inflammatory cytokines like IL-Ra and IL-10 are 
produced by rheumatoid synovium , they are insufficient to suppress the 
function and production of proinflammatory cytokines.  
I) Proinflammatory Macrophage And Fibroblast Cytokines:  
A) Interleukin -1 Family: 
 The IL-1 family includes a variety of polypeptides with a wide range of 
biological activity and they include IL-1α, IL-1β, IL-18, IL—33 and IL-Ra, a 
natural inhibitor of IL-1. 
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i) IL-1:  IL-1 is secreted abundantly by synovial macrophages, especially 
IL-1β.48 The IL-1activate B synoviocytes to proliferate and secrete a 
variety of mediators like IL-6, IL-8, GM-CSF and enhances the 
production of collagenase and prostaglandin. 
ii) IL-18: IL-18, in the presence of IL-12 has the ability to bias the immune 
response towards the Th1 phenotype. When IL-18 is inhibited in 
collagen induced arthritis, there is attenuation of  the disease.49  
Moreover IL-18 induces GM-CSF, expression of TNF and nitric oxide 
production by synovial macrophages.  
iii) IL-33: It is a novel cytokine signalling through ST2 surface recptors. It 
triggers the mast cells to release TNF-α and IL-17A in rheumatoid 
synovium. 
 
B) Tumour Necrosis Factor: 
 The TNF superfamily belongs to an extended group of related genes that 
has been found to play a major role in immune responses, inflammation, cell 
survival and apoptosis. TNF plays a key role as a proinflammatory cytokine in 
rheumatoid arthritis. It is detected in both rheumatoid serum and synovial fluid. 
TNF and  IL-1 have many similar functions like enhancing cytokine 
production, expression of adhesion molecules,  proliferation and MMP 
production. They have been found to share many functions and signal 
transduction pathways but the surface receptors and the intracellular signalling 
pathways they use are different. 
27 
 
 
 
TNF functions include  
 Stimulation of  PGE2 and collagenase production by human synovial 
cells. 
 Induction of bone resorption and inhibition of bone formation in vitro. 
 Inhibition of proteoglycan resorption and its biosynthesis in cartilage 
explants. 
 
 TNF blockade has been proved to be an effective anti inflammatory 
agent  and also it has been observed to decrease significantly  the destruction of 
extracellular matrix which  has been measured by radiographic progression.50 
 
C) IL-6 Family: 
 IL-6, a complex cytokine is produced by many types of cells like 
monocytes, T cells and FLS. Its functions include stimulation of B cells to 
produce immunoglobulins, differentiation of cytotoxic T cells and regulation of 
acute phase reactants like C-reactive protein.  
 
D) IL-12 Family: 
 It is a heterodimeric cytokine containing  p35 and p40 as its subunits 
and they play a key role in T cells differentiation and inflammation. The 
protein is produced by the macrophages in the rheumatoid joint and also by 
other antigen presenting cells like the dendritic cells.  
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E) IL-15:  
 IL-15 resembles IL-2 and regulates T cell chemotaxis and proliferation, 
production of immunoglobins by B cells and generation of natural killer ( NK) 
cells. Macrophages are the primary source of IL-15in RA. 
 
F) IL-32:   
 A novel cytokine, it activates NFκB pathway and induces the production 
of TNF, IL-1, IL-6 and IL-8. It has been demonstrated in the synovial lining 
macrophage- like cells.51 
 
G) Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF): 
 GM-CSF is a potent macrophage activator and causes induction of 
HLA-DR expression, IL-1 secretion, priming for increased release of TNF and 
PGE2. It also regulates neutrophil function by antibody dependent cytotoxicity, 
phagocytosis, chemotaxis and the production of oxygen radical. RA synovial 
tissue cells produce  GM-CSF which can be detected in RA synovial fluid.52 
 
H) Chemokine Families: 
 Chemokines belongs to a family of chemoattractant peptides, which 
with the help of adhesion molecules, attract the cells into the site of 
inflammation. The families include CC, CXC and CX3C which are classified 
according to the position of the characteristic cysteine residues. 
 
 IL-8, a CXC chemokine, is a potent neutrophil chemoattractant. This 
chemokine along with immune complexes and chemotactic peptides such as 
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C5a, lead to large influx of PMNs into the joint. IL-8 protein is demonstrated 
along the sublining perivascular macrophages.53 
 
 CXC family of chemokines include CXCL16 and Epithelial Neutrophil 
Activating Peptide-78 (ENA-78). CXCL16 binds to CXCR6 on T cells and 
contribute to the influx of lymphocytes into the synovium. 40% of the 
chemotactic activity of neutrophils in the RA synovial fluid is performed by 
ENA-78.54 
 
 CXCL13 is expressed by the follicular dendritic cells of  germinal 
centres found in the RA synovial tissues. They cause B cell migration in the 
RA joints.55 
 
 SDF-1 is another major chemokine which is expressed by synoviocytes 
and endothelial cells of  RA joints. They play a major role as T cell 
chemoattractant in the synovium through its receptor CXCR4. CXCR4 is 
highly specific for SDF-1and it is expressed by memory CD4+ lymphocytes. 
 
I) Platelet Derived Growth Factor (PDGF): 
 PDGF, a potent growth factor, is both chemoattractant and mitogenic for 
fibroblasts inducing collagenase expression. The isoforms of this molecule 
include PDGFA through PDGFD and all are detected in the RA synovial 
membranes.  
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J) Fibroblast Growth Factor(FGF): 
 FGFs belong to a group of peptide growth factors that stimulates 
angiogenesis. FGFs are present in RA synovial fluid and are expressed by 
synovial cells. 
 
SUPPRESSIVE CYTOKINES AND CYTOKINE ANTAGONISTS:  
 A number of suppressive and anti-inflammatory factors try to re-
establish homeostasis by suppressing the proinflammatory cytokine network in 
RA. These include IL-1RA, IL-10 and Transforming Growth Factor- β. It has 
been found that reduced production of these suppressive cytokines could lead 
to the perpetuation of the synovitis.56 
 
CLINICAL FEATURES: 
 In more than 2/3 rd of the patients there is an insidious onset with 
fatigue, generalized weakness and vague musculoskeletal symptoms. This 
persists for weeks or months before the specific symptoms develop. In 
approximately 10% of individuals there is an acute onset with rapid 
development of polyarthritis. 
 
 There is pain, swelling and tenderness in the joints of hands, wrist, 
knees and  feet. RA commonly causes symmetric arthritis usually affecting the 
proximal interphalangeal joints and metacarpophalangeal joints. Synovitis of 
wrist and knee joints are common features of RA. Axial involvement is usually 
limited to upper cervical spine. 
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 Extra articular manifestations include rheumatoid nodules, rheumatoid 
vasculitis, interstitial fibrosis, pneumonitis, pericarditis, Sjogren’s syndrome, 
Felty’s syndrome and osteoporosis.57 
 
BIOMARKERS IN RHEUMATOID ARTHRITIS: 
Acute phase reactants: ESR, CRP, IL-6. 
Autoantibodies: IgM RF, IgA RF, ACPA. 
Synovial vascularity: VEGF. 
Cartilage metabolites: MMP1 & 3, COMP – Cartilage oligomeric protein,              
C- terminal collagenII. 
Bone metabolites: Pyridonoline cross links, Carboxy terminal collagen I 
telopeptides. 
C- reactive protein(CRP): 
 CRP indicates disease activity in many inflammatory conditions. It is 
also used as a marker in RA. It was discovered by Tillet and Francis in the year 
1930, in acutely ill patients as a protein that binds to cellwall C- polysaccharide 
of streptococcus pneumonia. 
 
 It has a molecular weight of 23,028 Da and is made up of 5 identical 
polypeptide subunits.  It has a disc shaped structure with radial symmetry. Its 
half life is 18 to 24 hours. It is related to serum Amyloid P and pentraxin-3. It 
can provide nonspecific host defence and can activate classical complement 
pathway. 
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 A serum concentration of 5-10mg/L suggest an inflammatory process 
and it is also proportionate to tissue damage.58 
 
LEPTIN 
 Leptin, meaning “Leptos”( Greek word – thin), is a16kDa peptide 
containing 167aminoacid.59 It is produced by leptin gene that was originally 
discovered in ob/ob mice through positional cloning.60  It has been found to be 
structurally and functionally related to the type I cytokine superfamily. Though 
it plays a major role in food intake and energy homeostasis,  it also has other 
functions as in hypothalamic neuroendocrine regulation, insulin resistance, 
haematopoiesis, reproduction, inflammatory and immune response.61 
 
Leptin Gene:  
 
Figure 3 : Adapted from thenaturalhistorian.com 
 
 The ob protein, leptin was discovered in 1994 at Rockfeller University 
by a team led by Jeffrey Friedman.62It encodes  mRNA transcript of 4.5 
kilobase. The human ob gene has been localized on chromosome 7q31.3.63 
There are 3 exons and 2 introns encompassing 650 kb. The exons 2 and 3 
33 
 
 
contain the coding region of the ob protein. Initial studies have identified 
several regulatory elements within the promoter region of ob gene which 
includes cyclic AMP and glucocorticoid response elements, 
C/EBPα(CCAAT/enhancer binding protein), SP-1 and PPARγ binding sites. 64 
It has been observed that 84% of human leptin is identical to that of mouse and 
83% to that of rat leptin. It has been discovered that there is an intrachain 
disulphide bond that plays a significant role in the biological activity of 
leptin.65 
 
 Structural analysis of the molecule has suggested leptin as a globular 
protein whose tertiary structure resembles that of the haematopoietic cytokines 
like interleukins and GMCSF.66Leptin is produced mainly by white adipose 
tissue(WAT). A strong correlation has been found between leptin mRNA and 
adipose tissue protein levels and circulating levels of leptin. Leptin secreted by 
adipocytes is directly proportional to the amount of fat present in an 
individual67Moreover it has been observed that larger adipocytes contain more 
ob mRNA than the smaller adipocytes isolated from the same individual. 
 
 Very few human ob mutations have been identified so far. Montague et 
al first reported two children of consanguineous Pakistani family having ob 
gene mutation due to frameshift mutation.68Another three members of 
theTurkish family were identified by Strobel et al as having ob mutation due to 
missense mutation.69 Individuals having ob gene defect exhibit hyperphagia, 
hypothalamic hypogonadism and morbid obesity. Patients have been found to 
34 
 
 
have increased risk of mortality due to infections as there is immune system 
dysfunction.70  
 
Leptin expression and regulation: 
 The energy stores of fat in an individual decides the leptin expression. It 
has been observed that adipose ob mRNA and serum levels of leptin are 
increased in obese humans and in other mammals also.71Leptin levels increase 
in rodents within hours after a meal and in humans only after several days of 
overfeeding and it decreases in both the species within hours after initiation of 
fasting. Therefore the energy stores and energy balance are maintained by 
leptin.  
 
Table 4 Regulation of Leptin expressio
 
Courtesy Leptin  Rexford S.Ahima pg 416 
 Leptin expression by nutrition is partly regulated by insulin. In the 
feeding cycle when the insulin levels peak there is increased leptin 
expression.72. Leptin is expressed in response to cortisol also. An inverse 
correlation has been observed between the pulsatile secretion of the leptin and 
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cortisol and ACTH.73Higher levels of leptin are seen in the evening and early 
morning.73             
 
 There is a prepubertal spurt of leptin expression and this has been 
related to the gonadal axis maturation.74Females have been found to have 
higher leptin levels and this has been attributed to higher fat content and low 
testosterone levels.75Leptin synthesis is inhibited by testosterone but not by 
ovarian steroid hormones.76 
 
 In euthyroid patients there is correlation between leptin, TSH and 
adipose tissue. But in hypothyroidism and in hyperthyroidism there are 
conflicting reports.77 
 
 Infections, endotoxins and cytokines like IL-1, TNF, LIF stimulate 
synthesis of leptin.78.79 The secretion of leptin is decreased by cold exposure 
and catecholamines probably through β-adrenergic receptors. 80,81 
 
 Leptin is also secreted by extra adipose tissues like gastric fundic 
mucosa, skeletal muscle, placenta and mammary epithelia.82,83There is 
decreased synthesis of leptin in gastric fundus and increase in serum leptin on 
administrarion of cholecystokinin or gastrin and on feeding. 83Glucocorticoids, 
insulin and hypoxia stimulate leptin expression in the placenta.84Mammary 
epithelia also synthesize leptin which is secreted in the colostrums and 
absorbed by neonates.85 
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 Increased expression of  leptin in adipose tissue and denovo synthesis of  
leptin in the skeletal muscles of rats are observed on glucosamine infusion.86 
Administration of inflammatory stimuli like lipopolysaccharide (LPS) or 
turpentine increased leptin expression in adipose tissue and the circulating 
levels of leptin in hamsters. In sepsis a significant elevation in leptin levels 
have been demonstrated.  
 
DB GENE:  
 
Figure 4 : Courtesy Eiva Bernotiene et al,2006. 
 
 Leptin receptor (Ob-R) was first isolated by Tartaglia et al from the 
choroid plexus of the mouse.87It is a protein receptor that is encoded by the 
diabetes (db) gene. The Ob-R mRNA encodes six leptin receptor 
isoforms.88They include the long form Ob-Rb, the short form Ob-Ra,c,d,f and 
the soluble form Ob-Re. It has been observed that the leptin  receptor belongs 
to the family of class I cytokine receptors which include Interleukin-6(IL-6), 
Granulocyte colony stimulating factor(GCSF), leukemia inhibitory factor(LIF) 
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and glycoprotein 130(gp130).4 The extracellular ligand binding domain of the 
leptin receptor isoforms are similar at the amino terminus but are varying at the 
carboxy terminus. The five isoforms Ob-Ra, Ob-Rb, Ob-Rc, Ob-Rd and Ob-Rf  
contain transmembrane domain, but intracellular motifs that activate signal 
transduction pathways are seen only in Ob-Rb isoform.89 Ob-Re isoform lacks 
both transmembrane and intracellular domains and it has been found to 
circulate as soluble receptors. 
 
 Ob-Rb has been demonstrated in immune cells, T cells, NK cells, 
macrophages, polymorphonuclear cells, as well as neurons and intestinal 
epithelial cells.90 Leptin binds to the receptors and affect the physiological and 
metabolic functions by the activation of JAK/STAT signalling pathways. The 
short type receptor (Ob-Ra, Ob-Rc, Ob-Rd) has been found to be expressed in 
the choroid plexus, lungs, kidneys and liver. They help in leptin transport into 
brain tissue and also in the degradation and removal of leptin. The soluble 
receptor Ob-Re combine with the leptin in the blood circulation. It has been 
found that the Ob-Ra, Ob-Rb and the Ob-Re secreted by the placenta play a 
major role in leptin transportation and for it’s action in fetus and placenta. 91 
 
LEPTIN TRANSPORT AND SITES OF ACTION: 
 Though leptin is synthesized predominantly by adipocytes, it has been 
detected in low levels in the hypothalamus, pituitary, skeletal muscle, stomach, 
mammary epithelia, chondrocytes and a variety of other tissues. Leptin is 
partially bound to plasma proteins in the circulation.  
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 Leptin activates the neurons of arcuate, ventromedial and dorsolateral 
hypothalamic nuclei and also the brain stem neuronal circuits regulating the 
feeding behaviour and energy balance.92Brain microvessels express high levels 
of Ob Ra receptors and help in binding and internalising leptin.93Cerebrospinal 
fluid also can transport leptin into the brain through the Ob-Ra receptors which 
are highly expressed in choroid plexus.  
 
LEPTIN AND BODY FAT MASS:  
 Body weight is a non invasive predictor of body fat and caloric balance. 
Body mass index or “Quetelet Index” is a good index of body fat in both men 
and women. Serum leptin concentration correlates well with BMI in humans.67 
The mean serum leptin concentration is approximately four times higher in 
normal obese individuals than in lean healthy subjects. For a given BMI, the 
leptin levels in women is approximately twice that in men and this has been 
attributed to the testosterone.75  
 
LEPTIN & FEEDING BEHAVIOUR: 
 Leptin has been found to bind to membrane receptors in the various 
regions of the brain, particularly in the arcuate nucleus of the hypothalamus. 
One set of neurons expresses orexigenic (appetite stimulating) peptides, 
Neuropeptide Y (NPY) & Agouti  related peptide (AgRP). Leptin decreases the 
appetite by inhibiting the NPY and AgRP neurons, thus preventing the 
synthesis of orexigenic peptides. During fasting due to decrease in the leptin 
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concentration there is stimulation of NPY and AgRP production that results in 
increased appetite.  
 
 The second set of neurons containing the leptin receptors express 
proopiomelanocortin (POMC). Leptin binds to its receptors on the POMC 
neurons and make POMC to yield a variety of signal molecules, one among is 
Melanocyte stimulating hormone (MSH). MSH activates anorexigenic neurons 
and thus suppresses the appetite. On the other hand fasting inhibits MSH 
activity and stimulates eating. 94 
 
  “ Leptin is a bidirectional signal that switches physiological regulation 
between the fed and starved states.”95            
 
Figure 5 : Courtesy Williams textbook of endocrinology 12th edition 
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LEPTIN IN ENERGY BALANCE: 
 Leptin exerts its action on the sympathetic nervous system also. It 
increases the blood pressure, heart rate and also thermogenesis by uncoupling 
the mitochondria of white adipocytes. There is increased synthesis of the 
mitochondrial uncoupling protein thermogenin, a product of UCP 1 gene in 
adipocytes. Leptin alters the synaptic transmissions of the neurons in the 
arcuate nucleus to adipose and other tissues and stimulates thermogenin 
synthesis. Leptin causes an increased release of  norepinephrine in these 
tissues, which act through β3 adrenergic receptors and stimulate transcription 
of UCP1 gene. Thermogenin or UCP forms a channel in the inner 
mitochondrial membrane allowing protons to re-enter the matrix of the 
mitochondria without passing through the ATP Synthase complex. This leads 
to the continuous oxidation of fatty acids in an adipocye without ATP 
synthesis, dissipiating   energy as heat and consumption of dietary calories or 
stored fats in large amounts.96 
 
 Leptin infusion stimulates UCP-1 gene expression in brown adipose 
tissue, UCP-2 in white adipose tissue and UCP-3 in skeletal muscle and 
thereby increases energy expenditure.97  
 
LEPTIN IN CARBOHYDRATE AND LIPID METABOLISM:  
 Leptin is known for its role in the long term regulation of bodyweight, 
but independent of this role it exerts acute effects on metabolism. For example, 
it has been observed in the ob/ob mice leptin decreases glucose and insulin 
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levels acutely even before there is detectable weight loss and also stimulation 
of glucose metabolism and gluconeogenesis in wild type rodents.98,99,100 
 
 Leptin has been found to stimulate lipolysis.101 By its inhibitory effect 
on acetyl Co A carboxylase, it reduces the fatty acid and triglyceride synthesis 
and thereby decreases the intracellular concentration of lipids.102 Thus leptin 
has beneficial effects on β cell function and insulin resistance and thereby 
improves glucose homeostasis.101  
 
LEPTIN AND INSULIN: 
 Insulin secretion alike leptin depends on the body fat reserves and 
current energy balance. The insulin receptors in the appetite stimulating 
neurons of the arcuate nucleus inhibit the release of NPY and the insulin 
receptors present on the appetite suppressing neurons stimulate α MSH 
synthesis thereby reduces fuel intake and increases thermogenesis. 
 
 Leptin sensitizes the liver and muscle cells to insulin. This effect is 
explained by one hypothesis which states, “cross talk between the protein, 
tyrosine kinases activated by leptin and those activated by insulin; common 
second messengers in the two signalling pathways allow leptin to trigger some 
of the same downstream events that are triggered by insulin, through Insulin 
Receptors Substrate -2 (IRS-2) and Phospho Inositide 3-Kinase (PI-3K).” 
 
 The insulin receptor has intrinsic tyrosine kinase activity. When the 
leptin receptor is occupied by its ligand, phosphorylation occurs by a suitable 
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tyrosine kinase (JAK). The interaction between leptin and insulin is explained 
by the observation that both may phosphorylate the same substrate IRS-2, 
which activates PI-3K and thereby trigger the downstream consequences which 
include inhibition of food intake. IRS-2 acts as an integrator of the input from 
two receptors.103 
 
 
Figure 6 : Courtesy Lehninger Principles of biochemistry 5th edition. 
 
LEPTIN AND GROWTH HORMONE:  
 Leptin plays a significant role in the regulation of body fat mass, 
regulating food intake and energy expenditure, and thereby can act as a 
metabolic signal regulating growth hormone (GH) secretion.104 
 
 Leptin and NPY producing hypothalamic neurons synapse with the 
neurons of somatostatin and antisera to NPY and somatostatin reverse 
starvation induced GH release. 105 
 
 In hypopituitary adults with GH deficiency leptin concentration was 
found to be higher than could be expected for their body fat mass.106 
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LEPTIN AND THYROD HORMONE: 
 Rodent studies have shown that the fall in leptin levels associated with 
fasting can lead to thyroid axis suppression. In hypothyroid rodents low levels 
of leptin was observed. Infusion of  leptin into the cerebral ventricles reversed 
some of the metabolic changes seen in hypothyroidism, for example improving 
glucose  and reducing skeletal muscle fat.107 However human studies on leptin 
and thyroid hormones  showed contradicting results.108 
 
LEPTIN AND OTHER HORMONES: 
 On fasting when the leptin level falls there is rise in glucagon, 
epinephrine and glucocorticoids. The net effect of these adaptations stimulate 
neoglucogenesis and provide glucose for vital cellular function and fatty acids 
for the skeletal muscle.109 Studies have also shown that leptin is capable of 
regulating the hypothalamic-pituitary adrenal axis.110 
 
LEPTIN IN PUBERTY AND REPRODUCTION: 
 Leptin has also been observed to regulate positively the hypothalamic-
pituitary gonadal axis. This adipokine secreted by the peripheral adipocytes, 
plays a pivotal link between body fat and reproduction by signalling energy 
availability centrally.111 Leptin receptors are expressed on GnRH secreting 
neurons and it has been found that leptin accelerates GnRH pulsatality.112 
 
 The serum leptin levels in blood is tightly correlated with the body fat 
stores and a threshold level is required for the activation of the hypothalamic-
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pituitary gonadal axis. When serum leptin level increased during weight gain in 
treated patients with anorexia nervosa, it correlated positively with rise in 
gonadal steroids, testosterone, luteinizing hormone and follicle stimulating 
hormone. 113 
 
 The ob/ob mice, which lack leptin and the db/db mice, which lack leptin 
receptors were obese and exhibited hypogonadotropic hypogonadism and this 
provided an evidence for the significant role played by leptin in reproduction. 
There was partial reversal of hypogonadism when recombinant leptin was 
administered to the ob/ob mice and to rats having pubertal delay due to food 
restriction.114 
                   Serum leptin levels are increased during pregnancy and they are 
required for the growth of the fetus. Leptin secreted by the human placenta is 
identical to that produced by the adipose tissue. Energy deprivation is 
recognised rapidly than energy excess in pregnancy by the serum leptin 
concentration.109 
 
LEPTIN AND HAEMATOPOIESIS: 
 Leptin plays a significant role in haematopoiesis and this can be 
explained by the following observations in various studies: 
 Cytokine nature of leptin and it’s receptors. 
 Leptin receptor identification in the haematopoietic tissues. 
 Adipocytes are the most abundant stromal cell type in adult human 
bonemarrow.115 
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 Therefore it was thought that leptin in addition to serving as a local 
energy stores also played an important role in the regulation of haematopoiesis. 
Studies have also shown that leptin stimulate fetal and adult erythroid and 
myeloid series. It appears that the proliferating effect of leptin is mediated 
through the leptin receptor isoform, Ob-Rb, by JAK-STAT pathway.116  
 
LEPTIN RESISTANCE AND OBESITY: 
  “The failure to respond to anorexigenic effects of leptin is called leptin 
resistance.” 117 This leptin resistance could lead one to obesity.  
 
 Recent studies suggest that a group of proteins called Suppressors Of 
Cytokine Signalling play a major role in leptin resistance. These proteins by 
inhibiting receptor actions alter some hormone systems.  
 
 Insulin signalling pathways are initiated by autophosphorylation of 
tyrosine residues in the insulin receptor by leptin stimulation. SOCS proteins 
bind to the phosphorylated tyrosine residues on receptors or other members of 
the signal transduction pathway, and thereby disrupt signal flow and alter the 
cell’s biochemical activity. 117 
 
Other mechanisms involved in leptin resistance include the following:  
 Dysregulation in leptin synthesis and/or secretion. 
 Abnormalities in leptin transport in brain. 
 Abnormalities in leptin receptor and/or postreceptor signalling.118 
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 Leptin transport in CSF may be limited in obesity and this is evidenced 
in obese individuals by decreased plasma:CSF leptin ratio. Studies have also 
shown that leptin resistance can be mediated by theSH-2 containing tyrosine 
phosphatase, SHP-2, as leptin signalling is enhanced when the binding site on 
Ob-Rb for SHP-2 is mutated.119 
 
 Leptin interacts with other metabolic signals, especially insulin and 
glucocorticoids in the regulation of body weight. These hormones are involved 
in the feeding behaviour and body weight regulation by regulating the 
expression of similar neuropeptides in the brain. 
 
LEPTIN AND IMMUNE RESPONSE 
 
Figure 7 : Courtesy Tian et al 2014 
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 Leptin has wide regulation on immune response. It regulates the innate 
immunity by promoting phagocytic functions and inducing eicosanoid 
synthesis. It also influences nitric oxide and several proinflammatry cytokines 
synthesis by macrophages and monocytes.120 In murine macrophages, leptin 
increases IFN-γ induced expression of nitric oxide synthase. Leptin induces 
chemotaxis and release of reactive oxygen species. Finally leptin causes 
proliferation, differentiation, activation and cytotoxicity on natural killer(NK) 
cells.121 
 
 Leptin can also act on adaptive immune response. Adaptive immunity is 
classically divided into T helper 1(TH1) and T helper 2(TH2) pattern of cytokine 
secretion. TH1cells synthesize proinflammatory cytokines which is essential for 
macrophage activation and cell mediated responses, whereas TH2 lymphocytes 
produce anti-inflammatory modulators. Therefore for the optimal adaptive 
immune response there must be an adequate balance between TH1 and TH2 cell 
responses. Growth, differentiation and also T cell activation are influenced by 
leptin’s interaction with T-cell co-stimulating antigens such as CTLA-4 and 
dipeptidyl peptidase.  Glucocorticoid induced thymocytes apoptosis is 
prevented by leptin and thereby increases thymic cellularity.122  
 
 Leptin activates T cell and modifies T cell cytokine production pattern 
towards TH1 response.123 In leptin deficient individuals there was reduced 
number of CD4+ T cells with impaired T cell proliferation and cytokine 
release. Leptin receptors expressed on the human dendritic cells downregulate 
48 
 
 
their IL-10 production and drive the naive T cell proliferation towards a TH1 
phenotype. Thus from the above observations it is obvious that leptin plays a 
stimulatory role in adaptive immune response and favour TH1 polarisation. 
 
 The immune suppression observed in leptin deficient (ob/ob) mice, in 
starvation and in reduced calorie intake has been found to be due to leptin 
deficiency which reflects low amounts of stored energy in the adipose tissue. 
This impaired immune response was found to be reverted by exogenous leptin 
administration.124  
 
LEPTIN AS PROINFLAMMATORY MARKER:  
 Leptin regulates several cytokine secretion. It has been demonstrated 
that different inflammatory stimuli, like IL-1, IL-6 or lipopolysaccharide(LPS) 
can regulate mRNA expression as well as circulating leptin levels.125 
Furthermore, leptin is also produced by regulatory cells, suggesting that leptin 
expression could trigger or participate in the inflammatory process through 
direct, para or autocrine actions. 
 
 The reason behind the leptin dependent resistance in the development of 
innate immune mediated inflammation is unknown, but there are reports of 
imbalance between pro and anti- inflammatory cytokines,126 suggesting leptin 
mediated cytokine secretion in monocytes /macrophages through STAT 3 
activated pathway.127 In leptin deficient adaptive immune mediated 
inflammation models, an imbalance between TH1 and TH2 lymphocytes was 
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observed, which resulted in altered cytokine secretion leading on to resistance 
to inflammation. 
 
 Recent studies have shown elevated serum leptin levels in acute 
ulcerative colitis patients where it activates the nuclear factor –κB. Moreover it 
has been demonstrated that serum leptin levels are negatively correlated with 
CD4+ and CD25+ regulatory T cells suggesting that leptin might have a major 
implications  in the pathogenesis of different autoimmune disease s which is 
charecterised by TH1 autoreactivity.128  
 
LEPTIN AND SIGNALLING PATHWAYS:   
 Leptin binds to its receptor and brings about various biochemical and 
molecular mechanisms through certain signalling pathways. JAK-STAT 
pathway is one of the main signalling cascades and others are MAPK/ERK, 
AMPK and P13K. 
 
Figure 8 : Courtesy Tian et al 2014 
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i)JAK-STAT Pathway: 
 When leptin binds to leptin receptors it activates the JAK2 pathway by 
phosphorylating the tyrosine residues on the leptin receptor and induces the 
STAT-3 and STAT-5 pathway. The phosphorylated STAT-3 dimers enter the 
nucleus and function as transcription factors in the expression of targeting 
genes like SOCS3 and neuropeptides.129  
 
ii) MAPK/ERK Pathway:    
 After the phosphorylated tyrosine residues recruitment of SHP2, it 
activates the MAPK pathways, such as ERK1/2, p38 MAPK and p42/44 
MAPK, by its interaction with the GRB2 protein, which then enter the nucleus 
and mainly mediate chemokine and cytokine genes.130 
 
iii) P13K/Akt Pathway:  
 This is an important signalling pathway for leptin required for inducing 
immune and inflammatory responses. This pathway regulates various functions 
which includes the following:  
 Regulates anti-apoptotic transcription factor NF-κB in the production 
of various genes such as Bcl-2 and Bcl-XL.131 
 Akt can suppress the functions of transcription factor Fox01or 
FKHR-L1 which are involved in the production of Bim from Bcl-2 
family proteins and also in the direct regulation of  leptin functions 
in the hypothalamus. 
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 Stimulates insulin signalling such as IRS1/2 and participate in 
glucose metabolism.132 
 
iv)AMPK Pathway: 
 Studies have proved that leptin is involved in the regulation of 
CaMKK2/AMPK/ACC and the mTOR/ribosomal S6K pathways, thereby 
influencing the carbohydrate and lipid metabolism.133 
 
iv)Other Pathways:   
 When leptin binds to OB-Rb it stimulates PLC, which in turn activates 
c-Jun N-terminal protein kinase by activating PKC. It has also been reported 
that this PLC/PKC signalling system can act in the pancreatic islets in insulin 
release.  
 
LEPTIN AND RHEUMATOID ARTHRITIS: 
 Most studies have shown that interaction between neuroendocrine and 
immune systems lead to the pathogenesis of RA. Among the many 
neuroendocrine mediators, leptin is known to play a major role in the 
development of RA and in many studies elevated serum leptin levels has been 
demonstrated. Leptin regulates development, proliferation, apoptotic 
maturation and activation both in innate and adaptive immunity leading to 
inflammatory changes.  
 
 In RA patients as a proinflammatory cytokine, leptin increases IL-6 
production  by activating JAK/STAT pathway.134 Studies have indicated that it 
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also inhibits androstenedione secretion, which is anti-inflammatory, and this 
can perpetuate chronic inflammatory diseases.135 Seven et al observed that the 
serum and synovial fluid leptin levels were higher in RA patients when 
compared to the control group.  
 
 Among the multiple connective tissues found in the normal joint, the 
articular cartilage is the most affected in rheumatic diseases. The chondrocytes 
maintains a delicate balance between the synthesis and degradation of  the 
extracellular matrix and under pathological conditions this balance becomes 
altered  and a host of inflammatory mediators are produced by the 
chondrocytes leading to complete loss of articular cartilage. It has also been 
reported leptin along with IFN-γ and IL-1 induces NOS type II activation in the 
chondrocytes5by the signalling pathways that involves PI-3 Kinase, MEK-1 
and p38 Kinase and produces nitric oxide which is a well known 
proinflammatory mediator in the joint cartilage triggering chondrocyte 
phenotype loss, apoptosis and metalloproteases activation.  Therefore from the 
increased levels of leptin in the serum, synovial fluid and cartilage it is obvious 
that leptin plays a key role in the pathogenesis of RA.      
 
 Thus when the literatures were reviewed the significance of Leptin in 
immune regulation and autoimmunity was understood. Therefore this study 
was carried out to know about the Leptin status in RA patients so that future 
therapeutic measures can be decided in the treatment of RA.  
  
Aims & objectives 
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AIM OF THE STUDY 
 
 The aim of the study is to determine the concentration of leptin in the 
serum of Rheumatoid arthritis patients and to correlate it with the disease 
activity in those patients. 
 
The objectives of the study are 
 To compare the serum leptin concentration in rheumatoid arthritis 
patients with that of the apparently healthy individuals. 
 
 To correlate serum leptin levels with that of erythrocyte sedimentation 
rate, C- reactive protein and body mass index.  
  
54 
 
 
MATERIALS AND METHODS 
 
 This study was conducted after obtaining ethical committee approval 
from institutional ethics committee, Madras Medical college held on 20.01 
2015. A copy of the approval is enclosed. Volunteers were examined only after 
obtaining informed consent. A copy of the information sheet and the informed 
consent regarding the study is enclosed . 
 
STUDY DESIGN  : Case – Control Study         
 
STUDY CENTRE: Institute of Biochemistry and Department of 
Rheumatology, Madras Medical College.  
 
STUDY PERIOD : January 2015 – September 2015 
 
STUDY SUBJECTS SELECTION    
 CASES : 60 Rheumatoid arthritis patients diagnosed by the 
Rheumatologists in the Rheumatology OPD according to American College of 
Rheumatology (ACR) criteria 2010.  
 
INCLUSION CRITERIA:   
1. Rheumatoid arthritis patients diagnosed by American College of 
Rheumatology (ACR) criteria 2010 with symptoms of early morning 
stiffness of more than 1 hour , symmetrical joint involvement with 
pain, tenderness and swelling in the joints. 
2. Age 25-55years 
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EXCLUSION CRITERIA:  
1. Patients with Diabetes Mellitus, Hypothyroidsm, Hypertension, 
Coronary Vascular Disease. 
2. Patients on Estrogen & Statins. 
3. Pregnancy and lactation.  
 
DIAGNOSTIC CRITERIA FOR RHEUMATOID ARTHRITIS 
ACR /  European League Against  Rheumatism (EULAR) Criteria 2010 : 
Diagnostic criteria for Rheumatoid arthritis 
 The diagnosis is based on clinical and serological variables. The total 
score has  to be more than or equal to 6 for a diagnosis of Rheumatoid arthritis. 
 
Joint involvement: 
Small joints:- metacarpophalangeal joints, proximal interphalangeal joints, the 
interphalangeal joint of the thumb, second through fifth metatarsophalangeal 
joint and wrist.  
 
Large Joints:-  shoulders, elbows, hip joints, knees, and ankles . 
 1 large joint            -  0 point  
 2–10 large joints        -  1 point 
 1–3 small joints (with or without involvement of large joints)  - 2 points 
 4–10 small joints (with or without involvement of large joints)  - 3 points 
 More than 10 joints (with involvement of at least 1 small joint)  - 5 points 
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Serological Parameters:  
Rheumatoid factor and ACPA (anti-citrullinated protein antibody) 
 Negative RF and negative ACPA                      0 points 
 Low-positive RF or low-positive ACPA           2 points 
 High-positive RF or high-positive ACPA         3 points 
 
Acute phase reactants 
 Elevated erythrocyte sedimentation rate (ESR) / elevated CRP (c-
reactive protein) value - 1 point 
 
Duration of arthritis 
 For symptoms lasting six weeks or longer - 1 point 
 
CONTROLS: Age and sex matched apparently healthy volunteers among the 
students and staff of Madras Medical College. 
SAMPLE COLLECTION AND PROCESSING 
 5 ml of peripheral venous  blood was collected from the antecubital vein 
of these patients by applying tourniquet. Blood samples were collected from 
the patients around 9.00 am  to avoid diurnal variation of leptin in  fasting state 
and for uniformity in the collection. Serum was separated after clot formation 
and by centrifugation at 3000 rpm/min for 10 minutes. Serum was aliquoted 
and stored at -20˚C in the deep freezer until leptin was analysed. Other analytes 
were assayed as the samples were collected. 
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PARAMETERS  ASSESSED  
1. Serum Leptin. 
2. C-Reactive protein (CRP).  
3. Rheumatoid factor (RF). 
4. Serum Uric acid 
5. Serum Fasting Lipid profile. 
6. Serum Urea, Serum Creatinine  
7. Erythrocyte sedimentation rate(ESR) 
8. Haemoglobin 
 
CALCULATED PARAMETERS 
1.  BMI:- calculation 
 Body mass index was calculated using “Quetelet Index”.  
  BMI  = W (Weight in Kg) / H2 (Height in m)2 
  Grades of BMI 
   Normal           - 18.5 – 24.9 
   Overweight     - 25 –  29.9  
   Obese              - 30 and above 
 
2.  DAS 28(3) –  calculation 
     Disease activity score was calculated using the following formula 
DAS = [0.56*√T28 + 0.28* √S28 + 0.7* ln (ESR)]* 1.08 + 0.014* GH 
T- no of tender joints, S- no of swollen joints, GH – General Health 
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Grades of Disease activity 
< 3.2         low activity 
3.2 – 5.1   moderate activity 
> 5.1          high activity  
 
SERUM LEPTIN  ESTIMATION 
 METHOD: ELISA- Sandwich method 
 Kit Manufacturer : DRG 
PRINCIPLE  
1. Anti Leptin antibodies are coated on the microtitre wells. 
2. Test sera are applied. 
3. The sample is incubated with a specific biotinylated monoclonal 
antileptin antibody and forms a sandwich complex. 
4. After incubation the unbound material is washed off and enzyme 
complex is      added to detect the bound leptin. 
5. After incubation the unbound materials are again washed away. 
6. The substrate, TMB solution is added, which produces a color change 
by the action of the horse radish peroxidase enzyme present in sandwich 
complex. The intensity of the color developed is proportional to the 
concentration of the Leptin in the test sera.  
7. The reaction is stopped by the addition of dilute Sulphuric  acid. 
8. Absorbance is measured at 450 nm and the concentration is directly 
proportional to the colour developed. 
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MATERIALS REQUIRED 
1. Anti- Leptin  monoclonal antibody coated microtitre plate – 96 wells 
2. Assay buffer. 
3. Antiserum containing monoclonal biotinylated anti-Leptin antibody. 
4. Enzyme complex of strepavidin conjugated to horse radish peroxidase. 
5. Substrate solution – Tetramethyl benzidine.  
6. Stop solution –0.5M  Sulphuric acid (H2SO4)   
7. Standards:  
Std 0 0 ng/mL Lyophilised human serum free of Leptin. 
Std 1 2 ng/mL 
Leptin diluted in human serum – lyophilised. 
Std 2 5 ng/mL 
Std 3 25ng/mL 
Std 4 50 ng/mL 
Std 5 100 ng/ mL 
 
8. Controls  -   Low - 2.5- 6.6ng/mL       High – 24.4 – 45.4ng/mL 
9. Wash solution. 
10. Calibrated micropipettes - 15µL, 50 µL, 100µL. 
11. Deiodinised water. 
12. Disposable pipette tips. 
13. Absorbent paper. 
14. Microtitre plate reader with 450 nm 
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Reagent preparation  
1. All reagents and the microtitre wells strip were brought to room 
temperature. 
2. 0.5 mL of distilled water was added to lyophilised content of standard vials 
and allowed to stand for 10 minutes. Mixed gently several times before use. 
3. Control vials containing the lyophilised contents were reconstituted by 
adding 0.5mL of deiodinised water and allowed to stand for 10 minutes. 
Before use it was mixed gently for several times.  
4. Wash solution was prepared by adding 30 mL of concentrated wash 
solution with 1170 mL of distilled water to make it up to 1200mL.  
5. All other reagents were ready for use. 
 
PROCEDURE 
1. 15 µL of standard were pipetted in the1st 6 wells and study subjects serum 
added in the remaining wells. 
2. 100 µL of assay buffer added in all wells, mixed for 10 seconds. 
3. Incubated for 120 minutes at 20 -25˚c. 
4. Briskly shake out the contents of the wells. 
5. Machine washing was done 3 times using distilled wash solution, 300 µL 
wash solution was used per cycle for each well. The remaining fluid present 
in the wells were removed by striking the wells against absorbent paper. 
6. 100 µL of antiserum was added to each well. 
7. Incubated for 30 minutes at room temperature. 
8. Briskly shake out the contents of the wells. 
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9. The wells were rinsed by the machine 3times using 300 µL of wash solution 
per cycle for each well. The remaining fluid present in the wells were 
removed by striking the wells against absorbent paper. 
10. 100 µL of enzyme complex was added to each well. 
11.  Incubated for 30 minutes at room temperature. 
12. The wells were rinsed by the machine 3times using 300 µL of wash solution 
per cycle for each well. The remaining fluid present in wells were removed 
by striking the wells against absorbent paper. 
13. 100 µL of substrate solution was added in each well, gently shaken for 5 
seconds. 
14. Incubated in dark for 15 minutes at room temperature. 
15. 50 µL of stop solution was added in each well to stop the enzymatic 
reaction and  gently shaken for 30 seconds. 
16. Optical density was measured at 450nm in ELISA reader within 10 minutes 
after adding the stop solution. 
 
Calculation of results 
1. The  standard curve is plotted using concentration along x – axis & 
absorbance along  y- axis 
Leptin concentration ng/mL, absorbance 
0 0.0070 
2 0.2386 
5 0.4893 
25 1.2527 
50 2.0584 
100 2.3552 
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Using the absorbance values for each sample the concentration is calculated 
with the help of standard curve.  
Reference value : Male  : 3.84 + 1.79ng/mL 
                                 Female : 7.36 + 3.73ng/mL 
 
C- REACTIVE PROTEIN(CRP) ESTIMATION (Quantitative method) 
METHOD: Turbidimetric test. 
KIT USED: AVITEX TURBO CRP 
PRINCIPLE: The latex particles are coated with antibodies to human CRP. 
When the diluted is with mixed with samples containing CRP agglutination 
causes an absorbance change that can be quantified by comparing to a 
calibrator of known CRP concentration. 
 
REAGENTS: 
Latex: Suspension of polystyrene latex particles coated with goat Ig G 
antihuman CRP-concentrate. 
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Diluent: Tris buffer pH 8.2. Working strength. 
Calibrator: Calibrator serum containing CRP concentration of 55mg/L – 
lyophilized. 
Reagent preparation:  
Calibrator: Reconstitute with addition of 1mL of deiodinised water.mix 
thoroughly. Do not allow to foam. Bring to room temperature before use. 
Working reagent:1mL  concentrated latex + 9mL diluent. 
 
ASSAY PROCEDURE: 
1. Bring the working reagent and photometer cuvette holder to 37˚C. 
2. Semi autoanalyser was programmed for estimating the CRP by using 
the following parameters.  
Mode                                              - Fixed time  
Wavelength       - 540nm (530- 550nm) 
Temperature                              - 37˚C. 
Units               - mg/L 
No. of calibrators/standards        - 1 
Concentration of calibrator          - 55mg/L 
Blank      - Deiodinised water 
Sample volume               - 5µL 
Reagent volume             - 1000 µL 
No. of readings                               - 2 
Delay time secs                               - 5 secs 
Readtime     - 120 secs 
Normal low    - 0 mg/L 
Normal high                                 - 6 mg/L 
Linearity limit    - 150 mg/L                 
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Prepare sample: 
1.Pipette into a cuvette 1mL of working reagent.  
2. Add 5 µL of sample. 
3.Mix and read the absorbance immediately.(A1Sample) 
Prepare calibrator: 
4.Pipette into a cuvette 1mL of working reagent. 
5. Add 5 µL of calibrator. 
6. Mix and read the absorbance immediately. (A1Calibrator) 
7. Incubate at 37˚C. 
8.After 2 minutes read the absorbance of the sample (A2Sample) and the 
calibrator (A2Calibrator). 
 
Results and Interpretation: 
         (A2Sample)     -     (A1Sample)           x     Concentration of Calibrator 
         (A2Calibrator)   -   (A1Calibrator)        =    CRP mg/L 
Normal value upto 6mg/L. 
 
RHEUMATOID FACTOR  ( Semi Quantitative method) 
METHOD: Latex Agglutination 
KIT  USED: ACCUCARE 
PRINCIPLE: Rheumatoid factor present in serum agglutinates the latex 
particles coated with human gamma globulin. If the rheumatoid factor level in 
serum is greater than 8 IU/mL, agglutination will occur.  
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MATERIALS REQUIRED 
1. RF Latex reagent 
2. Positive control 
3. Negative control 
4. Glass slides 
5. Stirrer rods 
6. Droppers 
 
PROCEDURE 
1. 1 drop of serum,1 drop of positive control, 1 drop of negative control are 
added in different circles on the slide 
2. RF Latex reagent is added in all the circles. 
3. Stirrer is used to mix and spread the contents in test circle. 
4. The slide is rotated and observed for agglutination within 2 minutes. 
5. The samples showing agglutination are positive for Rheumatoid factor. 
6. These samples are quantitated by diluting with normal saline. 
7. Samples in these dilutions 1:2, 1:4, 1:8, 1:64 are prepared and subjected 
to the above described method until there is no agglutination.   
 
CALCULATION 
 RF = Highest dilution with positive reaction * 8 IU/mL ( reagent 
sensitivity) 
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 ESTIMATION OF SERUM CREATININE (Auto analyser) 
METHOD: Modified Jaffe’s  reaction. 
KIT USED: Erba Mannheim XL System Packs 
PRINCIPLE:  Creatinine reacts with alkaline picrate to produce a reddish 
orange colour. This is a non specific reaction. 
 
REAGENT COMPOSITION 
R1    
          Sodium hydroxide                240 mmoles/L 
R2     
          Picric acid                            26 mmoles/L. 
 
CALIBRATION: Done with serum based XL multical calibrator. 
ASSAY PARAMETERS: 
Primary wavelength    505 nm 
Secondary wavelength          570 nm 
Assay type                  Rate A 
Curve type                Linear. 
R1 volume                160 µL 
R2 volume                 40 µL 
Sample volume                10 µL. 
CALCULATION : Results are calculated automatically by the instrument. 
Reference values: 
Males: 0.7-1.4mg/dL. 
Females: 0.6-1.2mg/dL. 
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                         ESTIMATION OF SERUM UREA ( Autoanalyser) 
METHOD: Urease – Glutamate dehydogenase. 
KIT USED: Erba Mannheim XL System Packs 
PRINCIPLE:  
                       Urea is hydrolysed by urease enzyme to ammonia and carbon 
dioxide in the presence of water. 
                           Urea + H2O      Urease           NH3 + CO2 
Ammonia combines with alpha ketoglutarate in the presence of NADH to give 
glutamate & NAD 
NH3+ α ketoglutarate + NADH    Glutamate dehydrogenase      L- Glutamate + 
NAD 
The reaction is monitored by measuring the rate of decrease in absorbance at 
340 nm due to formation of NAD. 
REAGENT COMPOSITION: 
R1   
         Tris buffer                                  100mmol/L 
         Alpha – ketoglutarate                5.49 mmol/L 
         Urease ( Jack Bean)                  ≥ 10KU/ L             
         GLDH ( microorganism)          ≥ 2.5KU/ L 
R2     
         NADH                                      1.66 mmol/L 
CALIBRATION: Done with serum based  XL multical calibrator. 
ASSAY PROCEDURE: 
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Primary wavelength           340 nm 
Secondary wavelength       415 nm 
Assay type                          Rate A 
Curve type                          Linear 
R1 volume                          160µL 
R2 volume                          40µL 
Sample volume      2µL 
CALCULATION: Results are calculated automatically by the instrument. 
Reference range: 15-50 mg/dL. 
 
ESTIMATION OF SERUM URIC ACID 
METHOD: Uricase – POD. Trinder reaction.    
KIT USED: Erba Mannheim XL System Packs 
PRINCIPLE: 
 Uricacid in the presence of uricase is oxidised to allantoin. Peroxidase 
reacts with H2O2 catalyses the oxidative coupling of 4AAP with TOOS  to form 
Quinoneimine complex with the intensity of color is proportional to the 
concentration of uric acid in sample.The absorbance of final colour  measured 
at 546nm is proportional to the concentration of uric acid in the sample.   
 Uric acid + O2   + H2O          Uricase           Allantoin + CO2  + H2O2 
TOOS + 4AAP + 2 H2O2           Peroxidase        Quinoneimine  dye  + 4 H2O. 
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REAGENT COMPOSITION: 
R1 + R2  
         Pipes buffer (pH 7.0)                                 50mmol/L 
         TOOS                                                        0.48 mmol/L 
         Uricase                                                       ≥ 200U/ L             
         Peroxidase                                                  ≥ 5000U/ L 
         4 – Aminoantipyrine                                  1.5 mmol/L 
CALIBRATION: Done with  serum based  XL multical calibrator. 
ASSAY PROCEDURE: 
Primary wavelength           546 nm 
Assay type                          End point 
Curve type                          Linear 
R1 volume                          160µL 
R2 volume                          40µL 
Sample volume      4µL 
CALCULATION: Results are calculated automatically by the instrument. 
Reference Values: 
Men: 3.6-7.7mg/dL. 
Women: 2.5-6.8mg/dL. 
 
ESTIMATION OF HDL CHOLESTEROL ( Semiautoanalyser) 
METHOD: Phosphotungstic acid method, Endpoint assay. 
PRINCIPLE: 
Phosphotungstate precipitates Chylomicrons, LDL and VLDL  in the presence 
of divalent  cations. The supernatant ,which contains HDL cholesterol remains 
unaffected and is estimated using cholesterol reagent. 
Serum          Phosphotungstate           HDL + (Chylomicrons, LDL, VLDL          
                                                                                                Precipitate).  
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PRECIPITATING REAGENT: 
Phosphotungstic acid                2.4mmol/L. 
Magnesium chloride                 40mmol/l. 
 
PROCEDURE: 
1) Precipitation: Precipitation of LDL, VLDL, Chylomicrons. 500µL of 
precipitating reagent & 250µL of sample is mixed well and allowed to 
stand for 10 minutes at room temperature. Centrifuge for 10 minutes at 
4000 r.p.m to get a clear supernatant.  Concentration of HDL cholesterol 
is determined by using cholesterol reagent. 
2) Estimation with Cholesterol reagent: 50µL of supernatant is pipetted 
into 1000µL of Cholesterol working reagent and incubated for 10 
minutes at 37 C. Read the absorbance at 505 nm. 
 
CALCULATION: 
 HDL Cholesterol=Absorbance of test / Absorbance of Std x 
concentration of Std x 2 mg/dL  (2 is the dilution factor due to deproteinisation 
step). 
 
REFERENCE VALUES: 
 In Male : 35-55mg/dL 
 In Females : 45-65mg/dL. 
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ESTIMATION OF TOTAL CHOLESTEROL (Autoanalyser) 
METHOD : Cholesterol esterase-Cholesterol Oxidase. 
KIT USED : Erba XL System packs.  
PRINCIPLE: Cholesterol esterase hydrolyses  Cholesterol ester to Cholesterol 
free fatty acids. .It is acted upon by Oxidase to form cholest-4 en- 3- one and 
Hydrogen peroxide. Hydrogen peroxide reacts with aminoantipyrine  and 
phenol  to give  pink coloured complex  and its optical density measured at 
540nm. 
 Cholesterol ester + H2O      Cholesterol esterase       Cholesterol + Fatty acids. 
 Cholesterol + O2        Cholesterol Oxidase             Cholest-4-en-3-one + H2O2  
2 H2O2  + 4AAP + Phenol          Peroxidase              Quinoneimine dye + 4 H2O. 
 
REAGENT PREPARATION: 
Good’s buffer                                             50mmol/L 
Cholesterol oxidase                                     >50 U /L 
Cholesterol esterase                                     > 200U/L 
Peroxidase  (Horseradish)                           > 1200U/L 
4-Aminoantipyrine                                      0.3mmol/L 
Phenol                                                         5 mmol/L 
CALIBRATION: Done with  serum based  XL multical calibrator. 
ASSAY PROCEDURE: 
Primary wavelength                             505 nm 
Secondary wavelength                         700 nm 
Assay type                                            Endpoint 
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Curve type                                            Linear 
Reagent volume                                   200µL 
Sample volume                       2 µL 
 
CALCULATION: Results are calculated automatically by the instrument. 
Reference interval:150 - 260mg/dL. 
 
ESTIMATION OF TRIGLYCERIDES (Autoanalyser) 
METHOD: Glycerol-3-phosphate Oxidase (GPO) Method. 
KIT USED: Erba XL System packs.  
PRINCIPLE: Triglycerides (TGL) in the sample is hydrolysed by Lipoprotein 
Lipase to give glycerol and   free fatty acids. Glycerol is then acted upon by 
glycerol kinase to form glycerol-3-phosphate, which on action by oxidase is 
converted into DHAP & hydrogen peroxide. Hydrogen peroxide reacts with 4-
aminoantipyrine to give pink coloured complex. The intensity of colour is 
related to concentration of Triglyceride  in the sample. 
 
TGL + H2O                    Lipoprotein Lipase             Glycerol + Free Fatty acids. 
Glycerol + ATP             Glycerol Kinase             Glycerol-3-Phosphate  + ADP 
Glycerol-3-phosphate + O2            Glycerol-3-phosphate oxidase       DAP + H2O2                                                                   
H2O2 + 4AAP + TOOS                  Peroxidase            Quinoneimine dye + 2 H2O 
 
REAGENT PREPARATION: 
R1 
       PIPES buffer (pH 7.0)                               50 mmol/L 
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       ATP                                                           2.85 mmol/L  
       Mg                                                             60 mmol/L 
      Glycerol kinase (GK)                                > 1.5 U/mL 
      Glycerol-3-phosphate oxidase (GPO)       > 6.0 U/mL 
R2 
       Peroxidase                                                 > 15.0 U/mL                                                                        
      Lipoprotein Lipase                                    > 25.0 U/mL 
     4-Aminoantipyrine                                     1.5 mmol/L 
CALIBRATION: Done with  serum based  XL multical calibrator. 
ASSAY PROCEDURE: 
Primary wavelength                           546 nm 
Secondary wavelength                       700 nm 
Assay type                                          Endpoint 
Curve type                                          Linear 
R1                                                       160 µL 
R2                                                       40 µL 
Sample volume                     2 µL 
CALCULATION: Results are calculated automatically by the instrument. 
Reference Values:   Males: 60-165mg/Dl,  Females: 40-140mg/dL. 
 
Erythrocyte Sedimentation Rate : Measured by conventional Westegren 
Method 
Haemoglobin : Estimated by automated cell counter. 
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STATISTICAL ANALYSIS 
 
 Statistical analysis was performed using SPSS software version 22 and 
the following were carried out  
 Tests of significance at 5% significance using Unpaired student’s t-test 
was done to compare the Serum Leptin levels between cases and 
controls. 
 Pearsons correlation co-efficient was done to measure the linear 
relationship between serum Leptin concentration and other parameters 
like DAS28(3),  CRP, ESR and BMI.  
 One Way - ANOVA  Analysis of Variance to compare more than 2 
variables in the same group & between groups was carried out to 
compare serum Leptin concentration between four groups viz- RF & 
CRP positive, RF positive & CRP negative, RF negative & CRP 
positive, RF & CRP negative. 
  
Results 
  
S.no. Age Sex Duration Menstrual hty Ht Wt BMI ESR RF CRP Leptin DAS28(3) TC TGL HDL LDL Hb BP UA Urea Creati
1 55 M 1yr 160 60 23.44 50 Pos 12.49 12.93 5.57 137 84 60 60.2 11.2 130/80 10.3 32 0.9
2 45 F 10yrs Menopause 148 55 25.11 35 Neg 4.69 21.22 5.37 154 199 39 75.2 10.2 100/80 4.3 30 1.1
3 44 F 3yrs Reproductive 154 59 24.89 25 Pos 15.85 41.56 4.25 150 153 45 74.4 10.9 110/80 4.9 27 1
4 53 F 10yrs    Menopause 162 71 27.09 40 Pos 34 82.77 4.46 145 160 63 50 11.9 140/80 4.5 27 0.8
5 50 M 1.5yrs 148 48 21.9 48 Pos 13.75 38.29 5.11 166 141 54 83.8 12.6 100/70 8.2 28 0.9
6 38 F 2yrs Reproductive 152 67 29.1 15 Pos 12.58 45.92 4.21 163 90 78 67 11.4 130/80 4 25 0.8
7 55 F 3yrs Menopause 158 92 36.8 18 Pos 24 92.62 4.84 189 285 60 72 12.5 120/80 8.5 30 1.1
8 52 M 8yrs 162 57 21.75 24 Pos 20.6 56.53 5.23 224 194 51 134.2 11.8 100/60 4.5 36 1
9 43 F 2yrs Menopause 140 48 24.48 15 Neg 5.6 54.56 4.33 179 207 54 83.6 10.8 110/70 4.9 18 0.8
10 45 F 2yrs Reproductive 148 60 27.39 20 Pos 38 88 5.04 178 104 66 91.2 8.5 130/80 4.2 46 1.6
11 48 M 1yr 170 60 20.76 40 Pos 27.22 18.541 5.07 156 130 66 64 13.6 120/70 7.2 18 0.8
12 54 F 3yrs Menopause 140 54 27.55 100 Pos 27.65 82.17 6.6 122 97 42 60.6 11.4 120/70 3.9 26 0.8
13 36 F 2yrs Reproductive 145 53 25.22 30 Pos 9 11.48 5.95 144 106 78 44.8 10.8 100/70 4.5 20 0.7
14 41 F 20yrs Reproductive 139 55 28.55 40 Pos 4.12 12.95 5.6 201 135 45 129 11.8 110/70 3.2 29 1.1
15 32 F 2yrs Reproductive 148 58 26.5 20 Pos 38.12 93.11 5.49 195 146 51 114.8 12.4 110/70 6.6 22 1.3
16 36 F 4yrs Reproductive 145 39 18.57 46 Pos 18.72 5.28 6.28 145 122 39 81.6 10.2 110/70 4.3 26 1.1
17 43 F 8yrs Menopause 148 71 32.42 82 Pos 15.52 98.12 6 174 113 36 115.4 12.4 150/80 5.1 28 1.2
18 32 F 12yrs Reproductive 155 70 29.16 38 Pos 16.12 45.56 5.15 184 156 54 98.8 10.6 100/80 6.1 30 1.1
19 34 F 6yrs Reproductive 145 39 18.57 42 Pos 40.57 16.58 4.8 164 214 27 94.2 9.8 90/60 6.9 21 0.9
20 42 F 2yrs Menopause 155 63 26.25 47 Pos 18.12 58.54 4.89 215 155 36 148 12.4 100/70 3 19 1
21 40 M 1yr 160 76 29.68 26 Pos 13.02 16.96 5.02 167 152 69 67.6 11.5 120/80 5.6 25 1.3
22 45 F 3yrs Menopause 155 51 21.25 48 Pos 12.91 13.84 5.43 207 181 63 107.8 12.8 130/80 4.4 29 1.1
23 30 F 3yrs Reproductive 148 70 31.96 78 Pos 18.12 58.59 6.2 205 93 78 108.4 11.9 110/70 4.8 25 0.9
24 45 F 15yrs Menopause 140 44 22.44 20 Neg 13.48 53.71 4.69 205 92 54 132.6 10.6 100/70 5.9 32 1.2
25 43 F 11yrs Menopause 147 60 27.77 98 Pos 12 15.63 6.85 182 97 42 120.6 10.5 130/80 6.4 19 0.8
26 45 M 2yrs 158 71 28.4 42 Pos 26.51 88.56 5.66 166 100 42 104 13.8 130/80 6.4 21 0.7
27 28 F 3yrs Reproductive 152 54 23.38 35 Pos 13 24.09 5.51 210 85 42 151 8.1 100/70 5.8 26 0.9
28 40 F 7yrs Reproductive 147 66 30.55 35 Pos 36 96.24 5.03 217 132 57 133.6 12 100/70 6.7 26 1.1
29 32 F 11yrs Reproductive 158 70 28 20 Neg 16.15 93.18 5.61 206 93 54 133.4 12.8 110/80 12.9 29 1
30 41 F 3yrs Reproductive 157 71 28.8 10 Neg 13.04 49.18 4.16 270 105 36 213 11.2 110/80 3.4 23 0.8
31 50 F 5yrs Menopause 140 58 29.6 35 Neg 27 12.31 5.01 154 89 72 64.2 10.9 110/80 6 30 1.2
MASTER CHART FOR CASES    
S.no. Age Sex Duration Menstrual hty Ht Wt BMI ESR RF CRP Leptin DAS28(3) TC TGL HDL LDL Hb BP UA Urea Creati
32 32 M 10yrs 157 45 18.75 15 Pos 24.99 96.12 4.99 190 92 45 126.6 11.8 110/70 5.9 25 0.9
33 38 F 10yrs Reproductive 150 59 26.22 15 Pos 19.87 75.56 5.51 210 102 66 123.6 12.2 140/80 6.1 28 1.1
34 32 F 12yrs Reproductive 156 65 26.75 22 Pos 14.68 58.85 5.06 168 99 42 106.2 11 130/80 3.2 29 0.9
35 35 F 4yrs Reproductive 148 54 24.65 38 Pos 18 88.45 5.91 183 217 30 109.6 12.4 100/70 5.3 28 1.1
36 45 F 6yrs Menopause 150 64 28.4 40 Pos 5.8 16.14 5.82 219 211 51 125.8 12.2 130/80 6.3 28 1.3
37 40 F 2yrs Reproductive 145 66 31.42 10 Pos 5.6 49.18 3.5 254 105 48 185 14 100/70 3.9 24 0.8
38 45 F 5yrs Reproductive 152 68 29.43 15 Neg 15.02 15.65 3.92 215 231 30 138.8 11.8 110/70 7.2 23 0.9
39 32 F 8yrs Reproductive 150 52 23.11 55 Pos 17.34 16.64 4.9 141 80 33 92 12.4 120/70 2.8 24 0.8
40 41 F 4yrs Reproductive 139 48 24.9 25 Neg 5.74 39.56 4.51 181 99 24 137.2 10.2 100/60 4.3 26 0.9
41 39 F 2yrs Reproductive 148 41 18.72 20 Neg 12.93 13.53 4.2 171 105 36 114 9.8 90/60 3.9 22 0.9
42 42 F 5yrs Reproductive 152 58 25.1 65 Pos 4.6 27.17 5.03 193 206 33 118.8 10.4 110/70 4.6 26 0.8
43 44 F 3yrs Menopause 150 68 30.22 25 Neg 22.35 96.54 5.03 160 279 81 23.2 11.2 110/80 5.2 28 0.9
44 35 F 5yrs Reproductive 153 56 24.34 40 Neg 11.3 21.98 4.7 150 224 69 36.2 11.6 100/70 4.6 21 0.9
45 42 F 7yrs Reproductive 150 62 27.55 35 Pos 24.12 98.16 5.09 200 176 63 101.8 12.8 110/80 5.3 28 1.1
46 40 F 2yrs Reproductive 145 54 25.7 15 Pos 12.2 95.81 5.1 187 106 48 117.8 11.9 100/70 3.2 25 0.9
47 46 F 14yrs Reproductive 157 58 23.57 55 Pos 10.4 54.86 5.71 153 95 63 71 9.8 100/70 4.1 36 1.3
48 40 F 10yrs Reproductive 155 56 23.33 20 Neg 18.26 80.17 4.45 145 108 78 45.4 12.2 110/80 3.1 29 1.1
49 45 F 5yrs Reproductive 150 52 23.11 35 Pos 5.9 34.03 4.49 198 86 66 114.8 11.8 130/80 4.3 26 0.9
50 47 F 10yrs Reproductive 140 55 28.06 35 Pos 14.08 32.73 5.53 220 145 54 137 10.5 100/70 6.2 28 1.2
51 55 F 3yrs Menopause 160 82 32.03 22 Neg 20.06 89.12 5.2 207 104 36 150.2 11.6 140/80 4.3 32 0.9
52 35 F 1.5yrs Reproductive 158 78 31.33 37 Pos 23.19 91.65 5.29 192 273 33 104.4 10.2 100/70 3.6 19 0.7
53 29 M 4yrs 157 67 27.24 52 Pos 14.54 19.21 4.6 208 299 39 109.2 12.6 120/70 7.8 22 0.8
54 33 F 6yrs Reproductive 145 45 21.43 36 Pos 10.4 21.08 5.72 170 52 33 126.6 9.8 90/60 4 20 0.9
55 35 F 4yrs Reproductive 165 52 19.26 10 Neg 12.03 15.72 3.81 181 103 36 124.4 10.6 100/60 2.8 20 0.8
56 25 F 1yr Reproductive 160 52 20.31 15 Pos 31.92 26.17 3.99 95 108 30 43.4 11 100/70 4.3 18 0.7
57 26 F 3yrs Reproductive 152 60 26 45 Pos 34.63 93.18 5.38 204 140 54 122 12.4 120/70 3 21 0.8
58 45 F 8yrs Reproductive 165 60 22.05 15 Pos 13.6 32.75 4.3 196 186 33 125.8 11.2 110/80 3.6 28 1.1
59 35 F 4yrs Reproductive 138 36 18.94 20 Pos 12.12 12.01 4.14 193 239 63 82.2 9.6 90/60 4 24 0.9
60 50 F 4yrs Menopause 148 64 29.22 15 Pos 3.61 15.62 4.02 115 176 51 28.8 10.4 140/80 3.4 29 0.9
S.No. Age Sex Menstrual Hty Ht Wt BMI ESR RF CRP Leptin TC TGL HDL LDL Hb BP Uricacid Urea Creatinine
1 50 F Reproductive 154 68 28.7 16 neg 3 29.18 186 160 42 112 11.6 100/70 4.8 24 0.9
2 42 M 155 65 26.75 12 neg 5.2 19.55 184 256 39 93.8 12.4 130/70 5.6 22 0.8
3 27 M 158 65 26.1 10 neg 4.8 13.08 163 177 57 70.6 14.2 110/70 8.1 16 0.5
4 36 M 158 63 25.3 8 neg 5.7 10.6 104 87 33 53.6 13.6 110/80 5.9 18 0.9
5 32 M 165 62 22.8 10 neg 1.1 3.99 170 137 66 76.6 13.8 110/80 8.8 15 0.8
6 40 F Reproductive 164 66 23.54 6 neg 4.2 10.5 150 92 69 62.6 12.8 100/70 3 21 0.9
7 40 F Reproductive 153 61 26.5 14 neg 5.9 13.85 197 120 60 113 13.4 110/80 3.7 22 0.8
8 36 F Reproductive 150 83 36.39 22 neg 5.2 18.4 174 138 36 110.4 14.6 120/70 6 17 0.9
9 33 F Reproductive 145 58 27.62 13 neg 4.9 15.44 183 71 42 126.8 12.8 100/70 6 16 0.7
10 41 F Reproductive 148 61 27.85 22 neg 3.6 12.19 198 140 48 122 13.6 140/80 4.3 15 1.1
11 45 F Reproductive 150 61 27.11 15 neg 2.8 7.58 256 182 57 162.6 12.8 110/70 4.5 16 0.8
12 55 M 166 82 29.7 20 neg 3.1 5.99 220 275 33 132 13.8 130/80 11.3 22 1.2
13 31 F Reproductive 148 64 29.2 22 neg 3.8 9.34 193 140 63 102 11.8 100/70 4 18 0.8
14 36 F Reproductive 158 80 32.13 12 neg 5.7 12.54 161 179 36 89.2 13.8 120/70 4.4 16 0.7
15 24 F Reproductive 152 65 28.14 18 neg 5.3 10.58 138 252 33 54.6 12.4 120/80 6 19 0.9
16 43 F Reproductive 160 58 22.7 8 neg 3.2 6.44 168 115 39 106 11.6 110/70 4.5 15 0.8
17 48 F Menopause 162 86 32.82 17 neg 4.8 5.56 135 216 36 55.8 11.2 150/80 6.2 25 0.9
18 41 F Reproductive 154 66 27.8 12 neg 2.9 7.26 184 196 39 105.8 10.8 110/70 5.1 20 0.9
19 42 F Reproductive 155 81 33.75 9 neg 3.6 10.43 175 99 69 86.2 11.8 100/70 7.7 18 1.1
20 41 F Reproductive 157 75 30.49 10 neg 3.4 17.98 196 118 72 100.4 12.9 120/80 4.6 21 0.7
21 32 F Reproductive 152 80 34.6 20 neg 3.8 10.82 190 157 69 89.6 13.4 120/80 7 15 0.8
22 32 F Reproductive 150 71 31.55 13 neg 2.8 21.06 152 254 66 35.2 12.8 110/70 7.4 17 0.7
23 32 F Reproductive 153 62 26.95 15 neg 1.4 7.25 228 133 78 123.4 10.69 90/60 5.8 15 0.7
24 36 F Reproductive 153 66 28.7 21 neg 4.2 25.15 157 153 63 63.4 11.8 110/80 6.2 17 0.9
25 34 F Reproductive 145 46 21.9 6 neg 1.8 7.35 134 90 66 50 12.2 100/70 5.6 20 1
26 45 F Menopause 152 65 28.13 15 neg 4.6 14.31 128 98 66 42.4 11.4 110/80 2.7 25 1.1
27 52 F Menopause 157 75 30.49 12 neg 5.6 11.56 207 152 66 110.6 11 110/80 5.6 28 1.2
28 43 F Reproductive 140 65 33.16 15 neg 4.2 10.12 153 116 72 57.8 11.8 120/80 5 23 1
29 48 M 164 68 25.27 8 neg 1.8 4.41 164 143 42 93.4 13.4 120/80 6.2 26 1.2
30 41 F Reproductive 150 58 25.77 12 neg 2.1 5.6 172 136 51 93.8 11.2 100/70 3.5 21 1.1
MASTER CHART FOR CONTROLS
75 
 
 
RESULTS 
Table 1 Distribution of study population based on age 
 
Group 
Case Control Total 
N % N % N % 
Age 
group 
(yrs) 
< 30 5 8.3 2 6.7 7 7.8 
31 – 35 13 21.7 7 23.3 20 22.2 
36 – 40 10 16.7 6 20.0 16 17.8 
41 – 45 20 33.3 10 33.3 30 33.3 
46 – 50 6 10.0 3 10.0 9 10.0 
> 50 6 10.0 2 6.7 8 8.9 
Total 60 100.0 30 100.0 90 100.0 
 
 Table1 shows that the major study population belongs to the 30 to 50 
age group as observed in various studies.  
                             
Table 2 Distribution of study population based on gender 
 
Group 
Case Control Total 
N % N % N % 
Gender 
Male 8 13.3 6 20.0 14 15.6 
Female 52 86.7 24 80.0 76 84.4 
Total 60 100.0 30 100.0 90 100.0 
                 
 Table 2 shows the number of female and male patients in the study. This 
table shows that majority of the patients are female, and thus it indicates that 
women are more affected than men. 
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Table 3 Comparison of serum leptin levels between cases and 
controls in both males and females with RA 
 Group N Mean Std. Dev SE Mean t-Value P-Value 
Leptin 
Case 60 48.7777 32.00198 4.13144 
8.608 <0.001 S Control 30 11.9370 6.11431 1.11632 
S - Significant 
 Table 3 shows serum leptin concentration compared between cases and 
controls using unpaired student’s t-test. The mean serum leptin concentration 
was 48.78+32.00 ng/mL in cases and 11.94+6.11 ng/mL in controls. The 
standard error of mean for cases was 4.13 and that of the controls was 1.12. 
The 95 % confidence interval for mean serum leptin concentration in the cases 
was 56.88 ng/mL to 40.68ng/mL. The 95% confidence interval for mean serum 
leptin concentration in the controls was 14.13ng/mL to 9.75ng/mL. The p-value 
obtained was less than 0.001 and it was statistically highly significant.   
 
Figure1 Mean S.Leptin concentration in both females and males between  
cases and controls with RA 
.  
48.78
11.94
0.00
20.00
40.00
60.00
80.00
100.00
Case Control
M
ea
n 
S.
L
ep
tin
 le
ve
ls
 
(n
g/
m
L
)
Group
Mean S.Leptin level
77 
 
 
Table 4 Compare mean Serum Leptin concentration between cases and 
controls    ( Females) 
Gender  Group N Mean Std. Dev t-Value P-Value 
Female Leptin 
Case 52 49.6062 32.02568 
8.039 <0.001 S Control 24 12.5204 6.11400 
S – Significant 
 Serum leptin concentration among the females between cases and 
controls was compared using unpaired student‘s t-test. The mean leptin 
concentration in female patients with RA was 49.61+ 32.03ng/mL and in 
controls it was 12.52+ 6.11ng/mL. The difference in the mean between the two 
groups was statistically highly significant and the p-value was <0.001. 
 
Figure 2 Mean serum leptin concentration in female patients with RA 
and female controls. 
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Table 5 Comparison of serum leptin concentration in males  
between cases and controls. 
Gender  Group N Mean Std. Dev t-Value P-Value 
Male Leptin 
Case 8 43.3926 33.48337 
2.794 0.025 S Control 6 9.6033 6.05893 
  S - Significant             
 Table 5 compares the mean serum leptin concentration between the male 
RA patients and the male controls. The mean leptin concentration in male RA 
patients was 43.39+33.48ng/mL and in controls 9.60+6.06 ng/mL. The serum 
leptin concentration in both these groups was compared using student’s t- test. 
The difference in the mean between the two groups was statistically significant 
and the p-value was 0.025.  
 
Figure 3 Mean serum leptin concentration in  
male RA patients and male controls 
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Table 6 DAS 28 (3)  (Disease Activity Score) to grade disease activtity in 
patients with RA 
Disease Activity Score Case N % 
Low Activity 0 0.0 
Moderate Activity 34 56.7 
High Activity 26 43.3 
Total 60 100 
 
 Table 6 shows the percentage distribution of disease activity in RA 
patients. 56.7% of patients had moderate disease activity with a DAS Score of 
3.2 to 5.1. 43.3% of the patients had high disease activity with a DAS Score of 
more than 5.1. 
 
Figure 4 Disease activity in cases based on the DAS 28(3) in cases. 
 
  
Low Activity
0.0%
Moderate 
Activity
56.7%
High Activity
43.3%
Disease Activity Score among cases 
80 
 
 
Table 7 Comparison of Mean S.Leptin Concentration among patients with 
High and Moderate Disease Activity Score  
 Disease Activity Score N Mean Std. Dev 
t-
Value 
P-
Value 
Leptin 
Moderate Activity 34 46.8341 30.92205 
0.535 0.595 NS High Activity 26 51.3192 33.80734 
NS – Not Significant            
 
 Table 7 shows comparison of the mean serum leptin concentration 
among the RA patients with moderate and high activity using unpaired 
student’s t –test. Though the mean serum leptin concentration in high activity 
(n=26) was more (51.32+33.81ng/mL) than that in moderate activity (n=34) 
(46.83+30.92ng/mL), the difference in the mean between the two groups was 
not statistically significant and the p-value was 0.595. 
 
Figure 5 Mean serum leptin concentration in male and female RA patients 
with moderate and high disease activity 
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Table 8 Mean serum leptin concentration based on Body Mass Index in 
both patients and controls 
BMI Level Group S.Leptin (ng/mL) t-Value P-Value Number Mean Std.Dev 
Normal 
(BMI 18.5-
24.9) 
Case 25 35.6 24.99 
5.505 <0.001 Control 4 7.1 2.69 
Total 29 31.6 25.22 
Over wt 
(BMI 25-
29.9) 
Case 27 50.6 33.13 
5.789 <0.001 Control 17 12.4 6.86 
Total 44 35.8 32.16 
Obese 
(BMI 30 & 
above) 
Case 8 84.0 18.99 
10.248 <0.001 Control 9 13.2 4.95 
Total 17 46.5 38.71 
Total 
Case 60 48.8 32.00 
8.608 <0.001 S Control 30 11.9 6.11 Total 90 36.5 31.56 
S - Significant 
 Table 8 shows the mean serum leptin concentration between the normal, 
overweight and obese groups of RA cases and apparently healthy controls. The 
mean difference was compared using student’s t-test between the cases and 
controls, totally  and also between the groups. The mean serum leptin 
concentration in the normal group was 35.6+24.99ng/mL in cases and 
7.1+2.69ng/mL in controls, in the overweight group it was 50.6+33.13ng/mL in 
cases and 12.4+6.86ng/mL controls, in the obese group it was 
84.0+18.99ng/mL in cases and 13.2+4.95ng/mL in controls and totally it was 
48.8+32.0ng/mL in cases and 11.9+6.11ng/mL in controls. The mean 
difference between the cases and controls, totally and also between the groups 
was statistically significant with a p-value of <0.001.   
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Figure 6 Mean serum leptin concentration in normal, overweight and 
obese cases and controls          
 
  
Table 9 To compare mean serum CRP concentration between patients 
with RA and healthy controls 
 Group N Mean Std. Dev t-Value P-Value 
CRP 
Case 60 17.2872 9.25046 
11.043 <0.001 S Control 30 3.8167 1.36257 
 S - Significant             
 Table 9 shows the mean CRP concentration between cases and controls. 
The mean serum CRP concentration in cases was 17.29+9.25 mg/L and that of 
controls was 3.82+1.36 mg/L. The serum CRP concentrations was compared in 
both these groups using unpaired student’s t -test. The difference in the mean 
was statistically significant with a p-value of <0.001. 
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Figure 7 Mean serum CRP concentration in RA patients and healthy 
controls. 
 
 
Table 10 Comparison of seum  Leptin levels between CRP +v e & CRP –ve 
patients with RA 
Group  Sr. CRP Level N Mean Std. Dev t-Value 
P-
Value 
Case Leptin Positive 51 52.0830 33.12270 3.206 0.004 S Negative 9 30.0478 15.22072 
         S - Significant   
 Table 10 shows the mean CRP concentration between the CRP +ve 
cases and CRP –ve cases with RA. The mean serum leptin concentration in 
CRP +ve cases was 52.08+33.12mg/L and that of CRP –ve cases was 
30.05+15.22mg/L. The serum CRP concentration was compared in both these 
groups using unpaired student’s t -test. The difference in the mean was 
statistically significant with a p-value of <0.004. 
17.29
3.82
0.00
5.00
10.00
15.00
20.00
25.00
30.00
Case Control
M
ea
n 
S.
C
R
P 
le
ve
ls
 (m
g/
L)
Mean S.CRP level
84 
 
 
Figure 7 Mean serum CRP concentration in CRP+ve & CRP –ve  RA patients 
 
Table 11 shows the RF status in the patients with RA 
RF Number % 
Positive 46 76.7 
Negative 14 23.3 
Total 60 100.0 
 Table 11 shows the RF status in the RA patients. Patients with RF+ve 
was 76.7% and those negative was 23.3%.  
Figure 8 shows the Rheumatoid factor status in the RA patients. 
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 Table 12  Mean serum leptin concentration between RF+ve & RF-ve 
patients with RA 
 RF N Mean Std. Dev t-Value P-Value 
Leptin 
Positive 46 49.3528 32.37266 
0.250 0.803 NS Negative 14 46.8879 31.86361 
NS – Not Significant 
 Table 12 shows the mean leptin concentration between the RF +ve cases 
and RF–ve cases with RA.The mean serum leptin concentration in RF +ve  
cases  was 49.35+32.37ng/mL and that of RF–ve cases was 
46.89+31.86ng/mL. The serum leptin concentrations was compared in both 
these groups using unpaired student’s  t -test. The difference in the mean was 
not statistically significant and the p-value was  0.803. 
 
Figure 9 Mean serum leptin concentration in the  
RF +ve & RF –ve RA patients 
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 Table 13 One way ANOVA to compare leptin level in patients with 
RA between RF+ve & CRP +ve , RF+ ve & CRP-ve, RF-ve & CRP +ve, 
RF-ve & CRP –ve groups.    
 
Table 13a Oneway ANOVA to compare mean values between groups. 
Group N Mean Leptin Std. Deviation F-Value P-Value 
Case 
CRP+ve & RF+ve 40 52.8785 32.96044 
1.376 
 
0.259 
 
CRP –ve & RF+ve 6 25.8483 13.98779 
CRP +ve & RF-ve 11 49.1900 35.16968 
CRP -ve& RF -ve 3 38.4467 16.69786 
Total 60 48.7777 32.00198 
                                            
Table 13 b ANOVA Table 
Group Sum of Squares df Mean Square F-Value P-Value 
Case 
Between Groups 4149.266 3 1383.089 1.376 0.259 
Within Groups 56274.223 56 1004.897   
Total 60423.490 59   NS 
NS – Not Significant 
 Table 13 shows ANOVA was used to compare the mean serum leptin 
concentration between the 4 groups. The mean serum leptin concentration was 
higher in RA patients with both RF+ve and CRP+ve, than the other 3 groups 
viz,  CRP+ve alone,  RF+ve alone and both CRP and RF negative. The 
difference in the mean was not statistically significant; p-value  0.259.    
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Table -14 Comparison of mean ESR between patients with  
RA and healthy controls 
 Group N Mean Std. Dev t-Value P-Value 
ESR 
Case 60 34.48 20.001 
7.593 <0.001 S Control 30 13.77 4.826 
S - Significant 
 Table 14 shows the mean ESR level between the cases with RA and 
controls. The mean ESR level in cases with RA was 34.48mm/hr and that of 
controls was 13.77mm/hr. The ESR level was compared in both these groups 
using unpaired student’s t -test. The difference in the mean was statistically 
significant and the  p-value was <0.001. 
 
 Figure 10 Comparison of mean ESR between cases and controls. 
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Table 15 Correlation between DAS 28(3) and ESR in RA patients 
Group: Case ESR 
DAS 28(3) 
Pearson Correlation 0.695 
P-Value <0.001 
N 60 
             
 Table 15 shows the correlation between DAS 28(3) score and ESR in 
RA patients. Pearsons correlation coefficient was used to find the association 
between disease activity score and ESR. A moderate positive correlation was 
observed   between DAS and ESR with r value of 0.695 and this was 
statistically significant with a p-value of  <0.001. 
 
Table 16 Correlation between DAS (28) and Leptin in RA patients 
Group: Case DAS 28(3) 
Leptin 
Pearson Correlation 0.154 
P-Value 0.240 
N 60 
 
  Table 16 shows the correlation between leptin and DAS in RA patients. 
Pearsons correlation coefficient was used to find the association between leptin 
and DAS. No  correlation was observed between leptin and DAS (r =0.154) 
and this was not statistically significant.  
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Figure 11 Correlation between S.Leptin concentration and DAS28(3) 
 
Table 17 Correlation between ESR and Leptin in RA patients 
Group: Case ESR 
Leptin 
Pearson Correlation -0.064 
P-Value 0.627 
N 60 
         
 Table 17 shows the correlation between leptin and ESR in RA patients. 
Pearsons correlation coefficient was used to find the association between leptin 
and ESR. No correlation was observed between leptin and ESR( r = -0.064) 
and this was not statistically significant (p-value - 0.627).  
 
Table 18 Correlation between leptin and body mass index in RA patients 
BMI 
Pearson Correlation 0.423 
P-Value 0.001 
N 60 
              
 Table 18 shows the correlation between leptin and BMI in RA patients. 
Pearsons correlation coefficient was used to find the association between leptin 
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and BMI. A moderate positive correlation was observed between leptin and 
BMI with r value of 0.423 and this was statistically significant with a p-value 
of 0.001. 
 
Table 19 Correlation between CRP+VE and Leptin in RA patients 
Group: Case CRP+VE 
Leptin 
Pearson Correlation 0.44 
P-Value 0.001 
N 51 
 
 Table 19 shows the correlation between leptin and  CRP+ve RA 
patients. Pearsons correlation coefficient was used to find the association 
between leptin and CRP. A good correlation was observed between leptin and 
CRP with r value of  0.44 and this wast statistically significant with a p-value 
of 0.001.  
 
Figure 12 Correlation between S.Leptin concentration and CRP 
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Table 20 shows the charecteristics of study subjects. 
Variables Group N Mean Std. Dev t-Value P-Value 
Age (yrs) 
Case 60 40.75 7.501 
0.890 0.376 
Control 30 39.27 7.362 
Age (yrs) : 
Male 
Case 8 43.88 9.433 
0.728 0.480 
Control 6 40.00 10.412 
Age (yrs) : 
Female 
Case 52 40.27 7.149 
0.686 0.495 
Control 24 39.08 6.678 
Leptin 
Case 60 48.7777 32.00198 
8.608 <0.001 
Control 30 11.9370 6.11431 
BMI 
Case 60 25.8078 4.05917 
2.953 0.004 
Control 30 28.3970 3.62473 
CRP 
Case 60 17.2872 9.25046 
11.043 <0.001 
Control 30 3.8167 1.36257 
ESR 
Case 60 34.48 20.001 
7.593 <0.001 
Control 30 13.77 4.826 
TC 
Case 60 181.22 32.096 
1.010 0.315 
Control 30 174.00 31.702 
TGL 
Case 60 144.27 59.177 
0.658 0.512 
Control 30 152.73 54.112 
HDL 
Case 60 50.35 15.026 
0.974 0.333 
Control 30 53.60 14.712 
LDL 
Case 60 102.0133 37.36382 
1.544 0.126 
Control 30 89.8533 30.43509 
Uric acid 
Case 60 5.128 1.8616 
1.267 0.208 
Control 30 5.650 1.7980 
Urea 
Case 60 26.000 5.0321 
6.315 <0.001 
Control 30 19.433 3.7571 
Creatinine 
Case 60 .970 .1844 
1.894 0.062 
Control 30 .893 .1741 
 
< 0.05  -  Significant  
<0.01   -  Highly Significant 
>0.05   -  Not Significant  
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DISCUSSION 
 Rheumatoid arthritis is a chronic inflammatory autoimmune disease 
causing  functional disability by affecting the articular and extra-articular 
structures. The  disease is characterized by hyperplasia of the synovium, 
recruitment of inflammatory cells and in its later stages destruction of cartilage 
and bone. The disease is prevalent worldwide and it occurs by a complex 
interaction of genetic, environmental and immunological factors.2 
Autoimmunity plays a major role in the pathogenesis of  RA.  
 
 Studies have demonstrated that several cytokines released by 
monocytes, macrophages, Th1 and B cells play a significant role in the 
development of  RA. This brings about a break in the immune tolerance leading 
to autoimmune response. The tissue damage is caused by type III 
hypersensitivity reaction in AI diseases.9 The pathogenesis is explained in 
detail in the Review of literature.  
 
 Current hypothesis states that adipokines produced and released by the 
WAT, plays a major role in the occurrence of chronic proinflammatory state.3 
Changes in the blood levels of systemic and local adipokines or both have been 
demonstrated in various studies on inflammatory AI diseases. Of all Leptin has 
been investigated widely as it has been reported to play a pivotal role in the 
pathogenesis of many AI inflammatory diseases. 
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 Leptin was originally thought as a hormone regulating food intake and 
energy balance. Later studies revealed the significance of leptin as a 
neuroendocrine and immunity regulator.66 
 
The following features of leptin proves it as a proinflammatory cytokine.  
 Structural resemblance to type I cytokine superfamily. 
 Similarity of leptin receptor Ob-R to Class I cytokine receptor family. 
 Regulation of leptin expression by proinflammatory mediators. 
 Elevation of circulating leptin levels in both acute and chronic 
inflammation.  
 Leptin modulation of TH1/TH2 balance, regulating cytokine expression 
pattern.  
 Induction of NOS type II activation in chondrocytes by leptin in synergy 
with other cytokines.5 
 Moreover when the RA patients were made to fast, an improvement in 
the clinical parameters of disease activity was observed, with an associated 
decrease in serum leptin concentration and a shift towards TH2 cytokine 
production. Therefore from the above facts observed in the studies on RA 
patients,  it was suggested that leptin plays a significant role in the pathogenesis 
of RA.136 So this study was conducted to determine the serum leptin status in 
patients with RA and thereby aid in the future prospective in the control of 
undesired leptin actions in AI inflammatory disorder. 
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                   Sixty RA patients diagnosed by the Rheumatologists at the 
Rheumatology Out-Patient department of RGGGH, Chennai were selected for 
this study. The diagnosis was based on the American College of Rheumatology 
(ACR) Criteria 2010.137 Both RF+ve and RF-ve patients were included in the 
study. Thirty age and sex matched controls who had no clinical evidence of RA 
were selected. Serum Leptin, CRP, uric acid, lipid profile, urea, creatinine, RF, 
ESR and hemoglobin were determined in all 60 patients and 30 controls. 
Height, weight and blood pressure were measured for all the patients and 
controls. BMI was calculated by using “Quetelet Index” and disease activity 
was assessed by using the DAS 28(3) formula.138  
               In this study population 81.7% (49out of 60) were seen in the age 
group of 30-50 years of age which agrees with the literature where it is reported 
that 80% of the patients develop disease between 30- 50 years of age.1 Also 
among the cases, female patients 86.7% (52 out of 60) predominated as said in 
the literature that AI diseases predominate in women.2 
              Among the RA patients, 76.7% (n=46) were RF+ve whereas 23.3% 
(n=14) were negative for RF. RF positivity is a cardinal feature for RA 
although it is not specific for RA.  
             The RA patients exhibited CRP positivity in 85% (n=51) and 
negativity in 15% (n=9). 
                ESR was elevated in 80% (n=48) and was normal in 20% (n=12) of 
the RA patients. 
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 The disease activity score among the RA patients was moderate in 
56.7% (n=34) and high in 43.3% (n=26). 
 
 BMI was calculated for both cases and controls and they were  
categorized into normal, overweight and obese groups.  
 
 In this study the mean S.Leptin concentration among the cases (n=60) 
was 48.78+32.00ng/mL which was significantly higher than the control group 
(n=30) where it was 11.94+6.11ng/mL with a p-value of <0.001 which 
correlated with previous studies. 139 
 
 The mean S.Leptin concentration in the female patients (n=52) was 
49.60+32.03ng/mL which was higher than that of the female controls 
(n=24)12.52+6.11ng/mL which is statistically  significant.83 
 
 Similarly in the male patients (n=8) S.Leptin concentration is 
43.39+33.48ng/mL which was higher when compared to the male controls 
(n=6) 9.60+6.06ng/mL and it was statistically significant. All these correlate 
with the literature studies. 
 
 Mean S.Leptin concentration in patients with moderate disease activity 
(n=34) is 46.83+30.92ng/mL and that in high disease activity (n=26) is 
51.32+33.81ng/mL. Though the S.Leptin concentration in high disease activity 
was more than that in the moderate disease activity it was not statistically 
significant.140 
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 S.Leptin concentration in the patients with RA was higher than that of 
the controls based on BMI. The study showed that patients in the normal, 
overweight and obese categories showed elevated S.Leptin levels when 
compared to the same categories in the control group and it was also 
statistically significant. This reveals that there is association between BMI and 
leptin as proved in the literature. 67 
 
 The mean S.CRP concentration was higher 17.29+9.25mg/L in the cases 
(n=60) when compared to that 3.82+1.36mg/L of controls (n=30) and it was 
statistically significant.  
 
 The mean S.Leptin concentration in the CRP+ve patients (n=51) was 
52.08+33.12ng/mL and in the CRP-ve patients (n=9) was 30.05+15.22ng/mL 
and it was statistically significant. 
 
 An ANOVA comparison of mean S.Leptin concentration between the 4 
groups, RF & CRP positive, only RF positive, only CRP positive, both RF & 
CRP negative did not reveal any statistically significant difference in serum 
Leptin concentration. 
 
 Further in this study, the DAS showed no correlation with the S.Leptin, 
where the r value was 0.154 and it was not statistically significant.140 But there 
was a good correlation between BMI and S.Leptin levels with a r value = 0.423 
and it was statistically significant. 67A good correlation was also observed 
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between CRP and leptin which was statistically significant.141 All the above 
observations have been reported in previous studies.  
 
 So from the above discussion it is obvious that S.Leptin concentration is 
higher in RA patients when compared to controls and it was statistically 
significant. There was good correlation between S.Leptin and BMI, however 
there was no  correlation between S.Leptin levels and DAS which was not 
significant. Moreover a  good correlation was observed between leptin and 
CRP which was statistically significant. Thus the study reveals that leptinemia 
in RA patients is associated with the pathogenesis of RA. 
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SUMMARY 
 
 Many studies have suggested the significance of Leptin against AI 
diseases like RA, SLE, Multiple Sclerosis and Psoriasis. Blocking the leptin 
activity by using leptin mutants and leptin monoclonal antibody have been 
investigated widely as a strategy for the treatment of RA. The present study 
was carried out to assess the S.Leptin status in the patients with RA and to 
correlate it with the disease activity.  
 
 A case control study was carried out on 60 RA patients and 30 age and 
sex matched controls. The S.Leptin levels in RA patients was higher than that 
of the controls and it was statistically significant.  
 
From the above study we can come to an inference that  
 Leptin has a major role in the pathogenesis of RA by its effect on both 
innate and adaptive immunity. 
 As S.Leptin levels reflect the body fat mass, the BMI can be maintained 
in the normal category and thereby reduce the disease activity.   
 Therapeutic targets against leptin signaling can impair the humoral and 
cellular immune responses on specific target tissues and could be a 
useful beneficial therapy in the near future. 
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LIMITATIONS OF THE STUDY 
1. The number of male in the study population was low and more number 
of females were included in the study. 
2. Patients aged less than 25years and more than 55 years were not 
included in the study.  
3. The circadian rhythm of leptin could not be taken into consideration in 
this study. 
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SCOPE FOR FURTHER STUDIES 
1. As the serum leptin concentration is elevated in AI diseases, it can be 
evaluated in other AI disorders like SLE, Multiple Sclerosis and 
Psoriasis.   
2. As elevated circulating S.Leptin levels can contribute to low grade 
systemic inflammation, it can be studied in inflammatory disorders like 
Coronary Artery Atherosclerosis, Type II Diabetes Mellitus or 
Osteoarthritis. 
3. S.Leptin concentration can be studied in relation to other inflammatory 
cytokines in RA patients. 
4. Relationship between S.Leptin levels and radiographic joint damage in 
RA patients can be studied in future. 
5. Studies on therapeutic trials with leptin receptor antagonists can be tried. 
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INFORMATION SHEET 
Title : SERUM LEPTIN LEVELS IN RHEUMATOID ARTHRITIS 
 
Investigator         : Dr.S.Michael Rajam Geetha, 
                              Postgraduate, 
                              Institute of Biochemistry, 
                              Madras Medical College, 
                              Chennai-600003. 
 
Guide                 : Dr.V.K.Ramadesikan, 
                             Professor, 
                             Institute of Biochemistry, 
                             Madras Medical College, 
                             Chennai-600003. 
 
 Rheumatoid arthritis affects 1-2% of the general population.It affects women 3 
times more than men. It causes symmetrical synovitis, polyarthritis,  progressive joint 
damage, pain, disfigurement and disability. It also affects other systems like 
cardiovascular system, respiratory system, excretory system etc. Recent studies have 
shown that leptin, an adipocyte  hormone plays an important role in the pathogenesis 
of rheumatoid arthritis.By measuring the levels of leptin in rheumatoid arthritis 
patients we can know the significance of leptin in the causation of rheumatoid arthritis 
and thereby aid in the future diagnostic and therapeutic interventions. 
          Hence I am doing this study titled “Role of leptin in rheumatoid arthritis” at 
Rajiv Gandhi Govt. General Hospital, Chennai.To do this study I need to collect 5ml 
of blood from 60 rheumatoid arthritis patients and 30 apparently healthy individuals. 
While collecting the blood there will be no side effects. 
          Your identity will be kept confidential throughout the study and also during 
publication or presentation ofthe study findings in any clinical forum or journals. 
Participation in this study is purely voluntary. You can withdraw from this study at 
any time. Your decision will not result in any loss of benefits to which you are 
entitled. The results of the study will be intimated to you. If you have willingness to 
participate in this study, kindly sign in this information sheet and the consent form. 
 
 
Signature of the investigator                                Signature of  the participant 
                                                                              Thumb impression 
Place: 
Date:      
  
PATIENT CONSENT FORM 
Title of the study :" SERUM LEPTIN LEVELS  IN RHEUMATOID  
ARTHRITIS."  
Name :                           Date : 
Age :        OP No: 
Sex :        Project Patient No
 : 
Documentation of the informed consent 
I _____________________________ have read the information in this form (or it has 
been read to me). I was free to ask any questions and they have been answered. I  
hereby give my consent to be included as a participant in “SERUM LEPTIN 
LEVELS IN RHEUMATOID ARTHRITIS.” 
1. I have read and understood this consent form and the information provided to me. 
2. I have had the consent document explained to me. 
3. I have been explained about the nature of the study. 
4. I have been explained about my rights and responsibilities by the investigator.  
5. I have informed the investigator of all the treatments I am taking or have taken for 
the past  --------- months/years including any native (alternative) treatment. 
6. I have been informed about the risks associated with my participation in this 
study. 
7. I agree to cooperate with the investigator and I will inform him/her immediately if 
I suffer unusual symptoms. 
8. I have not participated in any research study within the past ________ month(s). 
9. I am aware of the fact that I can opt out of the study at any time without having to 
give my reason and this will not affect my future treatment in this hospital. 
10. I am also aware that the investigator may terminate my participation in the study 
at any time, for any reason, without any consent. 
11. I hereby give permission to the investigators to release the information obtained 
from me as a result of participation in this study to the sponsors, regulatory 
authorities, Govt. agencies, and IEC. I understand that they are publicly presented. 
12. I have understood that my identity will be kept confidential even if my data are 
publicly presented. 
13. I have had my questions answered to my satisfaction. 
14. I have decided to be in the research study. 
 
I am aware that if I have any question during this study, I should contact the 
investigator. By signing this consent form I attest that the information given in this 
document has been clearly explained to me and understood by me, I will be given a 
copy of this consent document. 
For  participants: 
Name and signature / thumb impression of the participant (or legal representative if 
participant  in competent/For age 10-17 yrs-Name& signature of the parent/guardian.) 
Name ____________________________ Signature with date_______________ 
  
Name and Signature of impartial witness (required for illiterate patients): 
Name ____________________________ Signature with date_______________ 
Address and contact number of the impartial witness: 
 
Name and Signature of the investigator or his representative obtaining consent: 
Name ___________________                    Signature with Date_____________  
  
   
   
   
PROFORMA 
Date :        Sample Id :  _____________ 
Name :    Age :   Sex :  Ht (cm):  Wt (kg) :  
Pre/Post Menopausal: 
Ethnicity :    Community :   Duration of 
Symptoms/diseases  
Treatment history : 
Pregnancy       Lactation          
Other Autoimmune Diseases : ___________________   if any duration ________________ 
Associated diseases with duration : 
Renal Failure                       PCOS        Hypertension      
Ischaemic heart disease          Tuberculosis       Diabetes Mellitus  
    
 Hypothyrodism                     others        
Drug Intake: 
 Statins                   
 Any other medications _______ 
Smoking :____________Passive Smoking :__________ Alternative Medicine intake:______ 
Clinically : 
1. 2 /  swollen joints : _________________________ 
2. Morning stiffness lasting more than 1hr for atleast 2 weeks : __________________ 
3. RF  : Positive / Negative  
4. Symptoms of hypothyroidism: 
5. Blood Pressure: 
BMI           :     
DAS 28 (3) : 
Sample Collection  :  Date ________________ Time __________ 
Sample Analysis  :  Date ________________  
 
Investigations : 
            Hemoglobin  : 
 CRP   : 
 Sr.Leptin  : 
Sr.Fasting Lipid Profile : 
ESR   : 
Rheumatoid Factor : 
             DAS 28(3)  
JOINTS LEFT RIGHT 
 
Total Swollen Joints : 
 
Total Tender Joints : 
 
Swollen Tender Swollen Tender 
Shoulder     
Elbow     
Wrist     
MCP 
1     
2     
3     
4     DAS 28 (3)Score Activity 
5     < 3.2 Low 
PIP 1     3.2 to 5.1 Moderate 
2     > 5.1 High 
3      
4     
5     
Knee     
SUB 
TOTAL 
      
 
 
 ACR CRITERIA 2010 – POINTS 
 
 1 large joint  - 0   Negative RF/ Negative ACPA   - 0    
 2-10 large joint  - 1    Low positive RF/ Low positive ACPA  - 2     
 1-3 small joints with or without - 2   High positive RF / High positive ACPA - 3     
Large joint involvement 
 4-10 small joints with or without – 3  Elevated ESR / Elevated CRP  - 1     
Large joint      
 >10 joints with involvement of  - 5   Duration of arthritis   - 1     
atleast 1 small joint       six weeks or longer 
 
    TOTAL POINTS :  ____________________ 
 
 
 
